<SEC-DOCUMENT>0001610618-24-000051.txt : 20240424
<SEC-HEADER>0001610618-24-000051.hdr.sgml : 20240424
<ACCEPTANCE-DATETIME>20240424160934
ACCESSION NUMBER:		0001610618-24-000051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240423
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240424
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		24870627

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdtx-20240423.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:52c897aa-3db6-4be1-b6e1-6239c81be01d,g:cd5fc6b2-e88f-4fee-81a2-854ad3fb7286,d:6e863db4d7384fc3bc160779c920da8b-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20240423</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-24">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20240423.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-23</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6e863db4d7384fc3bc160779c920da8b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 23, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Cidara Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:234pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36912</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-1537286</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">6310 Nancy Ridge Drive,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 101</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">San Diego,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">752-6170</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.839%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">CDTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:10pt;padding-left:121.5pt;text-indent:-121.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Current Report on Form 8-K, &#8220;Cidara Therapeutics,&#8221; &#8220;Cidara,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Cidara Therapeutics, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology Transfer and License Agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2024 (the &#8220;Signing Date&#8221;), the Company and Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) entered into a license and technology transfer agreement (the &#8220;Janssen License Agreement&#8221;) related to drug-Fc conjugates (&#8220;DFCs&#8221;) based on the Company&#8217;s Cloudbreak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform for the prevention and treatment of influenza (&#8220;Influenza Program&#8221;), including CD388, the Company&#8217;s most advanced DFC program, which has completed a Phase 2a clinical trial. All applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the transactions contemplated by the Janssen License Agreement expired prior to the execution of the Janssen License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Influenza Program was the subject of an exclusive license and collaboration agreement between the Company and Janssen dated March 31, 2021, and effective as of May 12, 2021 (the &#8220;2021 Collaboration Agreement&#8221;), the material terms of which are described in Note 9 to the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10&#8209;K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission on April 22, 2024, and are incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Janssen License Agreement became effective upon the Company&#8217;s payment in full to Janssen of the upfront payment described below, which was paid on April 24, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of 2021 Collaboration Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen License Agreement, the 2021 Collaboration Agreement, including the license granted by the Company to Janssen and the Company&#8217;s non&#8209;compete covenant thereunder, terminated, and the Company assumed responsibility for further clinical development, manufacture, registration and commercialization of DFCs within the Influenza Program (&#8220;Compounds&#8221;), including CD388, and products containing Compounds (&#8220;Products&#8221;), including Products containing CD388 (&#8220;CD388 Product&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Technology Transfer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen License Agreement, Janssen granted the Company an exclusive, worldwide, fee-bearing but royalty-free license under certain Janssen-controlled technology to develop, manufacture and commercialize Compounds, including CD388, and Products, including CD388 Product. In addition, Janssen agreed (i) to transfer and disclose to the Company certain Janssen-controlled know-how related to CD388 and CD388 Product, including manufacturing know-how, CMC data and documentation, and other data and reports, (ii) to transfer all existing quantities of CD388 and CD388 Product clinical material (including drug substance, drug product and certain components of CD388) and GLP-grade CD388 and components thereof, and (iii) to transfer to the Company the cell banks used by or on behalf of Janssen for the production of CD388 and components thereof.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a condition to the effectiveness of the Janssen License Agreement, the Company paid Janssen an upfront payment of $85 million. The Company will also be obligated to pay Janssen up to $150 million in development and regulatory milestone payments with respect to CD388 Product and up to $455 million in commercialization milestone payments with respect to CD388 Product. The Company has no obligation to pay any royalties to Janssen on the sale of any Product and no obligation to pay any milestone payment or other amount to Janssen with respect to the development, registration, manufacture or commercialization of any Compound other than CD388 or any Product other than CD388 Product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Either party may terminate the Janssen License Agreement for uncured material breach by the other party, or in the event the other party becomes subject to bankruptcy or similar insolvency proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Janssen License Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Janssen License Agreement, which will be filed with the Securities and Exchange Commission as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2024 (the &#8220;Signing Date&#8221;), the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional and other accredited investors (the &#8220;Purchasers&#8221;), pursuant to which the Company issued and sold, in a private placement (the &#8220;Private Placement&#8221;), 240,000 shares of Series A Convertible Voting Preferred Stock, par value $0.0001 per share (the &#8220;Series A Preferred Stock&#8221;), at a purchase price of $1,000 per share. The closing of the Private Placement took place on April 24, 2024 (the &#8220;Closing Date&#8221;) and the Company received total gross proceeds of $240 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock, which was filed with the Secretary of State of the State of Delaware on the Closing Date (the &#8220;Certificate of Designation&#8221;), each share of Series A Preferred Stock is, subject to the Stockholder Approval (as defined below) and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain beneficial ownership conversion limitations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, automatically convertible into shares of common stock, par value $0.0001 per share, of the Company (the &#8220;Common Stock&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and limitations contained in the Certificate of Designation, the Series A Preferred Stock issued in the Private Placement will not become convertible until the Company&#8217;s stockholders approve the issuance of all Common Stock issuable upon conversion of the Series A Preferred Stock (the &#8220;Conversion Shares&#8221;) and an amendment to the Company&#8217;s certificate of incorporation to increase the authorized number of shares of Common Stock to enable the issuance or reservation for issuance, as applicable, of all of the Conversion Shares (the &#8220;Stockholder Approval&#8221;). On the first Trading Day (as defined in the Certificate of Designation) following the announcement of the Stockholder Approval, each share of Series A Preferred Stock shall automatically convert into Common Stock, at the conversion price of $14.20 per share, rounded down to the nearest whole share, subject to the terms and limitations contained in the Certificate of Designation, including that shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company&#8217;s outstanding shares of Common Stock as of the applicable conversion date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Securities Purchase Agreement, as soon as practicable following the receipt of the Stockholder Approval (the &#8220;Filing Date&#8221;) (and in any event no later than twenty days thereafter), the Company shall file a registration statement providing for the resale by the Purchasers of the Registrable Shares (as defined in the Securities Purchase Agreement) and shall use commercially reasonable efforts to have the registration statement declared effective within fifteen days following the Filing Date or, in the event that the staff of the Securities and Exchange Commission reviews and has written comments to such registration statement, within forty-five days following the Filing Date. The Company further agreed to keep such registration statement continuously effective until all Registrable Shares have been resold or no Registrable Shares remain outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities Purchase Agreement contains </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customary representations, warranties and covenants that were made solely for the benefit of the parties to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase Agreement. Such representations, warranties and covenants (i) are intended as a way of allocating risk between the parties to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase Agreement is included with this filing only to provide investors with information regarding the terms of transaction and not to provide investors with any other factual information regarding the Company. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in satisfaction of a condition to closing of the Private Placement, two members of the Board of Directors of the Company (the &#8220;Board&#8221;) tendered their resignations from the Board, the size of the Board was increased to nine, and the Company appointed three directors to the Board, as more fully disclosed in Item 5.02 below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No statement in this Current Report on Form 8-K or the attached exhibits is an offer to sell or a solicitation of an offer to purchase the Company&#8217;s securities, and no offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Support Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Securities Purchase Agreement and as a condition to closing of the Private Placement, the executive officers, directors and certain stockholders of the Company entered into support agreements (the &#8220;Support Agreements&#8221;) providing, among other things, that such executive officers, directors and stockholders will vote all of their shares of Common Stock: in favor of (i) the issuance of all Conversion Shares upon conversion of the Series A Preferred Stock in compliance with Nasdaq Listing Rule 5635(b) and/or (d), (ii) an amendment to the Company&#8217;s certificate of incorporation to increase its authorized number of shares of Common Stock to enable the issuance or reservation for issuance, as applicable, of all of the Conversion Shares (without regard to any limitations on conversion set forth in the Certificate of Designation) in compliance with the rules and regulations of Nasdaq (together, the &#8220;Transaction Proposals&#8221;), (iii) an increase to the reserved shares under the Company&#8217;s 2015 Equity Incentive Plan of an amount no greater than 2,334,000 shares, and (iv) other customary annual stockholder meeting matters (together, the &#8220;Additional Proposals&#8221;), and against any proposal that conflicts or materially impedes or interferes with the approval of any of the Transaction Proposals or Additional Proposals or that would adversely affect or delay the consummation of the transactions contemplated by the Securities Purchase Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Securities Purchase Agreement, the Certificate of Designation and the Support Agreements and the transactions contemplated thereby do not purport to be complete and are subject to, and qualified in their entirety by reference to, the complete text of the Securities Purchase Agreement, Certificate of Designation and form of Support Agreement, which are filed as Exhibits 10.1, 3.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.02 Termination of a Material Definitive Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained above in Item 1.01 is hereby incorporated by reference into this Item 1.02.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effectiveness of the Janssen License Agreement, the 2021 Collaboration Agreement, including the license and right of first negotiation granted by the Company to Janssen and the Company&#8217;s non&#8209;compete covenant thereunder, terminated, and the Company assumed responsibility for further clinical development, manufacture, registration and commercialization of Compounds, including CD388, and Products, including CD388 Product.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.02 Unregistered Sales of Equity Securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock and Conversion Shares are being sold and issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no established public trading market for the Series A Preferred Stock and the Company does not intend to list such securities on any national securities exchange or nationally recognized trading system.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b) Resignation of Directors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2024, in accordance with the terms of the Securities Purchase Agreement, each of Timothy R. Franson, M.D., and David Gollaher, Ph.D. tendered their resignations from the Board, contingent on and effective as of immediately prior to the closing of the Private Placement. The resignation of each of Drs. Franson and Gollaher is not a result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d) Appointment of Directors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of the closing of the Private Placement, the Board increased the number of directors to nine and upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Merson, Ph.D., Ryan Spencer, and Laura Tadvalkar, Ph.D., as directors of the Company. Dr. Merson will serve as a Class III director with an initial term expiring at the Company&#8217;s 2024 annual meeting of stockholders, Mr. Spencer will serve as a Class I director with an initial term expiring at the Company&#8217;s 2025 annual meeting of stockholders, and Dr. Tadvalkar will serve as a Class II director with an initial term expiring at the Company&#8217;s 2026 annual meeting of stockholders, in each case, until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal. Concurrent with his appointment to the Board, Dr. Merson was appointed as a member of the Nominating and Corporate Governance Committee of the Board.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Tadvalkar, Mr. Spencer, and Dr. Merson were each appointed to the Board pursuant to the terms of the Securities Purchase Agreement. Dr. Tadvalkar currently serves as a managing director at RA Capital Management, L.P., which purchased $100 million of Series A Preferred Stock in the Private Placement through its affiliated fund, RA Capital Healthcare Fund, L.P. There is no transaction involving either Mr. Spencer or Dr. Merson that requires disclosure under Item 404(a) of Regulation S-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Tadvalkar, Mr. Spencer, and Dr. Merson will each be entitled to receive cash and equity compensation for their service as a director of the Company pursuant to the Company&#8217;s amended and restated non-employee director compensation policy (the &#8220;Director Compensation Policy&#8221;), a copy of which is filed as Exhibit 10.5 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-36912), filed with the Securities and Exchange Commission on April 22, 2024. Notwithstanding the terms of the Director Compensation Policy, effective as of the second trading day following the filing of this Current Report on Form 8-K, Dr. Tadvalkar, Mr. Spencer, and Dr. Merson will each receive an initial option grant to purchase 85,000 shares of the Company&#8217;s common stock, with one-third of the shares vesting on the one-year anniversary of the date of grant and the remaining two-thirds of the shares vesting over the following two-year period such that the initial grant is fully vested on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third anniversary of the date of grant. In addition, Dr. Tadvalkar, Mr. Spencer, and Dr. Merson will each be paid a $40,000.00 annual cash retainer for their service on the Board, and Dr. Merson will also be paid a $4,000 annual cash retainer for his service as a member of the Nominating and Governance Committee of the Board, each payable in arrears on a quarterly basis and pro-rated for any partial months of service.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into its standard form of indemnity agreement with each of Dr. Tadvalkar, Mr. Spencer, and Dr. Merson, a copy of which is filed as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S&#8209;1 (File No. 333-202740), as amended, originally filed with the Securities and Exchange Commission on March 13, 2015.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained above in Item 1.01 is hereby incorporated by reference into this Item 5.03.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Securities Purchase Agreement, on the Closing Date, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware designating 240,000 shares of its authorized and unissued preferred stock as Series A Preferred Stock, with a stated value of $1,000 per share (the &#8220;Original Per Share Price&#8221;). The Certificate of Designation sets forth the rights, preferences and limitations of the shares of Series A Preferred Stock. The following is a description of the terms of the Series A Preferred Stock:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At all times following the Closing Date, while shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted basis and without regard to any limitations on conversion set forth in the Certificate of Designation or otherwise) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock (other than a stock dividend on the Common Stock payable solely in the form of additional shares of Common Stock).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to certain limitations described in the Certificate of Designation, the Series A Preferred Stock is voting stock. Holders of the Series A Preferred Stock are entitled to vote together with the Common Stock on an as-converted basis. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders. Unless and until the Company has obtained the Stockholder Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series A Preferred Stock (solely for purposes of calculating the number of aggregate votes that the holders of Series A Preferred Stock are entitled vote to on an as-converted basis) will be equal to that number of shares equal to 19.9% of the Company&#8217;s outstanding Common Stock as of the Signing Date (excluding for purposes of the calculation, any securities issued on such date) (the &#8220;Cap&#8221;), with each such holder being able to vote the number of shares of Series A Preferred Stock held by it relative to the total number of shares of Series A Preferred Stock then outstanding multiplied by the Cap. Notwithstanding the foregoing, the holders of the Series A Preferred Stock are not entitled to vote on the Transaction Proposals. Additionally, prior to the Stockholder Approval, and as long as at least 20% of Series A Preferred Stock remains outstanding, the Company shall not, without the approval of 65% of the then outstanding shares of Series A Preferred stock, amend the Certificate of Designation, issue additional equity securities senior to or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Series A Preferred Stock, pay any dividends on the Series A Preferred Stock, Common Stock, the Company&#8217;s Series X Convertible Voting Preferred Stock, par value $0.0001 per share (the &#8220;Series X Preferred Stock&#8221;) or any other equity securities junior to or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Series A Preferred Stock or repurchase any equity interests, or incur additional indebtedness in excess of $500,000.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Prior to the Stockholder Approval, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, including a change of control transaction, or Deemed Liquidation Event (any such event, a &#8220;Liquidation&#8221;) the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a Deemed Liquidation Event, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or the other proceeds available for distribution to stockholders, before any payment shall be made to the holders of any other shares of capital stock of the Company by reason of their ownership thereof, an amount in cash per share equal to three times the Original Per Share Price, together with any dividends accrued but unpaid thereon (the &#8220;Liquidation Preference&#8221;). If upon any such Liquidation, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full Liquidation Preference, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the payment in full of all Series A Liquidation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preference, the remaining assets of the Company available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series A Preferred Stock pursuant to the Certificate of Designation shall be distributed among the holders of shares of Series A Preferred Stock, the Series X Preferred Stock, and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations set forth in the Certificate of Designation or otherwise. Following the Stockholder Approval, upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed among the holders of the shares of Series A Preferred Stock, Series X Preferred Stock, and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth in the Certificate of Designation or otherwise. Following the Stockholder Approval, there will be no Liquidation Preference on the shares of Series A Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of terms of the Series A Preferred Stock and the Certificate of Designation do not purport to be complete and are subject to, and qualified in their entirety by reference to, the complete text of the Certificate of Designation which is filed as Exhibit 3.1 to this Current Report on Form 8-K and are incorporated herein by reference.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit312024-04x24.htm">Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit312024-04x24.htm">Reference is made to Exhibit 3.1.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012024-04x24.htm">Securities Purchase Agreement, dated April 23, 2024, by and among Cidara Therapeutics, Inc. and the purchasers named therein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1022024-04x24.htm">Form of Support Agreement.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (embedded within the inline XBRL document).</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: April 24, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit312024-04x24.htm
<DESCRIPTION>CERTIFICATE OF DESIGNATION
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i18e7a931ae3944fea7da7704d37b457f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">EXECUTION VERSION</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CIDARA THERAPEUTICS, INC.<br>CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERIES A CONVERTIBLE VOTING PREFERRED STOCK</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION&#160;151 OF THE<br>DELAWARE GENERAL CORPORATION LAW</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in accordance with the provisions of Section&#160;103 of the Delaware General Corporation Law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) does hereby certify that, in accordance with Sections 141(c)&#160;and 151 of the DGCL, the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or a committee of the Board of Directors acting upon authority delegated by the Board of Directors, which resolution remains in full force and effect on the date hereof&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to authority expressly set forth in the Certificate of Incorporation of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the issuance of a series of Preferred Stock designated as the Series&#160;A Convertible Voting Preferred Stock, par value $0.0001 per share, of the Corporation is hereby authorized and the designation, number of shares, powers, preferences, rights, qualifications, limitations and restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series) are hereby fixed, and the Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Voting Preferred Stock is hereby approved as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERIES A CONVERTIBLE VOTING PREFERRED STOCK</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the purposes hereof, the following terms shall have the following meanings&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule&#160;144 under the Securities Act of 1933. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the number of shares of Common Stock equal to 19.9% of the Corporation&#8217;s outstanding Common Stock as of the Signing Date, rounded down to the nearest whole share (excluding for purposes of the calculation, any securities issued on the Signing Date).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Corporation&#8217;s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified into.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date on which the Series A Preferred Stock is converted pursuant to Section&#160;6.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for the Series&#160;A Preferred Stock shall be $14.20 per share of Common Stock,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series&#160;A Preferred Stock in accordance with the terms hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Deemed Liquidation Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;a merger or consolidation in which (i)&#160;the Corporation is a constituent party or (ii)&#160;a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)&#160;the surviving or resulting corporation&#59; or (2)&#160;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation&#59; or (b)&#160;the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the Delaware General Corporation Law.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules&#160;and regulations promulgated thereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Excluded Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any holder of Series&#160;A Preferred Stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means April 24, 2024.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 5(a).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Original Per Share Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means $1,000 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Requisite Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date that the Corporation&#8217;s stockholders first approve the Proposals. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Requisite Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Holders of at least sixty-five percent (65%) of the then outstanding shares of Series A Preferred Stock, voting together as a single class.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series X Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2(c).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2(a).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Share Conversion Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 6(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Signing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the effective date of that certain Securities Purchase Agreement for the purchase and sale of the Series A Preferred Stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Standard Settlement Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the standard settlement period, expressed in a number of Trading Days, for the Company&#8217;s primary trading market or quotation system with respect to the Common Stock that is in effect on the Conversion Date, which as of the Issuance Date was &#8220;T+2.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a day on which the Common Stock is traded for any period on a principal securities exchange or if the Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which the Common Stock is then being traded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Designation, Amount and Par Value&#59; Assignment&#59; Ranking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The distinctive serial designations of the series of Preferred Stock designated by this Certificate of Designation shall be designated as the Corporation&#8217;s Series&#160;A Convertible Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series&#160;A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The number of shares of Series A Preferred Stock so designated shall be 240,000. The Series&#160;A Preferred Stock shall have a par value&#160;of $0.0001 per share.</font></div><div style="text-align:justify;text-indent:2.25pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Corporation shall register shares of the Series&#160;A Preferred Stock, upon records to be maintained by the Corporation&#8217;s transfer agent for that purpose (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series&#160;A Preferred Stock Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in the name of the Holders thereof from time to time. The Corporation and its transfer agent may deem and treat the registered Holder of shares of Series&#160;A Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. Shares of Series&#160;A Preferred Stock may be issued solely in book-entry form.&#160;The Corporation or its transfer agent shall register the transfer of any shares of Series&#160;A Preferred Stock in the Series&#160;A Preferred Stock Register, upon surrender of the shares of Series A Preferred Stock evidencing such shares to be transferred, to the Corporation&#8217;s transfer agent. Upon any such registration or transfer, a new or book-entry notation evidencing the shares of Series&#160;A Preferred Stock so transferred shall be issued to the transferee and a new book-entry notation evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring Holder, in each case, within three Business Days. The provisions of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall be enforceable by any such Holder.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Prior to the Requisite Approval, the Series A Preferred Stock will be senior to the Series X Convertible Preferred Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Series&#160;X Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Common Stock and all other series or classes of stock and equity securities of the Corporation with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary Liquidation. Following the Requisite Approval, the Series A Preferred Stock will rank </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Series X Preferred Stock, Common Stock and all other series or classes of stock and equity securities of the Corporation with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary Liquidation.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At all times following the Issuance Date, while shares of Series A Preferred Stock are issued and outstanding, holders of Series A Preferred Stock shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series&#160;A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock (other than a stock dividend on the Common Stock payable solely in the form of additional shares of Common Stock). No other dividends shall be paid on shares of Series A Preferred Stock. Dividends shall be paid only if, when and as declared by the Board.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the last sentence of this Section 4(a), Section 4(b) and Section 6(f), the Series A Preferred Stock is voting stock. Holders of the Series A Preferred Stock are entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock basis as determined by dividing the Original Per Share </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price with respect to such shares of Series A Preferred Stock by the Conversion Price. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Accordingly, holders of Series A Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series A Preferred Stock is then-convertible on all matters submitted to a vote of stockholders. Unless and until the Corporation has obtained the Requisite Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series A Preferred Stock (solely for purposes of calculating the number of aggregate votes the Holders of Series A Preferred Stock are entitled to vote on an as-converted basis) will be equal to that number of shares equal to the Cap, with each such holder being able to vote the number of shares of Series A Preferred Stock held by it relative to the total number of shares of Series A Preferred Stock then outstanding multiplied by the Cap (without regard to any limitations on conversion set forth in Section 6(a)). Notwithstanding the foregoing, (i) the Holders of the Series A Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis on the Proposals set forth in Section 8 herein and (ii) the voting rights set forth in this Section 4(a) are subject to the limitations set forth in Section 6(f)).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In addition to Section 4(a), prior to the Requisite Approval and as long as at least 20% of Series A Preferred Stock remains outstanding, neither the Corporation nor any of its subsidiaries shall take any of the following actions without the consent of the Requisite Holders (which consent rights, for the avoidance of doubt, shall terminate upon receipt of the Requisite Approval)&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">amend or waive any provisions of their respective organizational documents, including this Certificate of Designation of Preferences, Rights and Limitations, in a manner that adversely and disproportionately affects the rights, preferences, privileges or power of the shares of Series A Preferred Stock&#59;</font></div><div style="margin-bottom:10pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">issue additional equity securities senior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Series A Preferred Stock&#59;</font></div><div style="margin-bottom:10pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">pay any dividends on the Series A Preferred Stock, Common Stock, Series X Preferred Stock or any other equity securities junior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Series A Preferred Stock or repurchase any equity interests&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">incur additional indebtedness in excess of $500,000.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Following receipt of the Requisite Approval, the Corporation shall not, without the consent of the Requisite Holders, alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Prior to the Requisite Approval, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, including a change of control transaction, or Deemed Liquidation Event (any such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in the event of a Deemed Liquidation Event, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or the other proceeds available for distribution to stockholders, before any payment shall be made to the holders of any other shares of capital stock of the Corporation by reason of their ownership thereof, an amount in cash per share equal to three times (3X) the Original Per Share Price, together with any dividends declared but unpaid thereon (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidation Preference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If upon any such Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full Liquidation Preference, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the payment in full of all Series A Liquidation Preference, the remaining assets of the Corporation available </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series A Preferred Stock pursuant to the paragraph above shall be distributed among the holders of shares of Series A Preferred Stock, Series X Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of this Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth herein or otherwise and without regard as to whether sufficient shares of Common Stock are available out of the Company&#8217;s authorized but unissued stock for the purpose of effecting the conversion of the Series A Preferred Stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Following the Requisite Approval, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of the shares of Series A Preferred Stock, Series X Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all shares of Series A Preferred Stock as if they had been converted to Common Stock pursuant to the terms of this Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth herein or otherwise and without regard as to whether sufficient shares of Common Stock are available out of the Company&#8217;s authorized but unissued stock for the purpose of effecting the conversion of the Series A Preferred Stock. For the avoidance of doubt, following the Requisite Approval, there will be no Liquidation Preference on the shares of Series A Preferred Stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">No Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Prior to the receipt of the Requisite Approval, subject to Section 4(a) above, the Series A Preferred Stock is not convertible by the Holder thereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Automatic Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;Subject to the limitations set forth in Section 6(f), on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Trading Day following the public announcement of the Requisite Approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Automatic Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), each share of Series A Preferred Stock shall automatically convert into the number of shares of Common Stock equal to the quotient of (A) the Original Per Share Price, plus all declared and unpaid dividends, divided by (B) the Conversion Price, rounded down to the nearest whole share of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Share Conversion Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any conversion in accordance with this Section 6(b) would (i) cause a holder to beneficially own a number of shares of Common Stock that exceeds the amount that could be issued to such holder pursuant to Section 6(f) or (ii) in the reasonable judgment of the applicable holder, result in a violation by such holder of the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended from time to time (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">HSR Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then, at the Automatic Conversion Date, (x) only such portion of such holder&#8217;s shares of Series A Preferred Stock that may be converted without exceeding the limitations in Section 6(f) and without resulting in an HSR Violation shall be converted to Common Stock and (y) the remaining shares of Series A Preferred Stock that would otherwise have been converted into Common Stock shall remain outstanding as Series A Preferred Stock.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Conversions at Option of Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section 6(a) and the limitations set forth in Section 6(f), at the option of the Holder thereof, each share of Series A Preferred Stock, shall be convertible into a number of shares of Common Stock equal to the quotient of (A) the Original Per Share Price, plus all declared and unpaid dividends, divided by (B) the Conversion Price, rounded down to the nearest whole share of Common Stock.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Mechanics of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Holders shall effect optional conversions pursuant to Section 6(c) by providing the Corporation and its transfer agent with the form of conversion notice attached hereto as&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), duly completed and executed. The Notice of Conversion must specify the number of shares of Series A Preferred Stock to be converted, the number of shares of Series A Preferred Stock owned prior to the conversion at issue, and the number of shares of Common Stock to be issued in respect of the conversion at issue. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the DTC participant account nominated by the Holder through </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DTC&#8217;s Deposit Withdrawal Agent Commission system (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DWAC Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The date on which such an optional conversion shall be deemed effective (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Optional Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and together with the Automatic Conversion Date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), shall be defined as the Trading Day that the Notice of Conversion, completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business hours by, the Corporation and its transfer agent. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Delivery of Electronic Issuance Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Not later than the number of Trading Days comprising the Standard Settlement Period after the applicable Conversion Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Corporation&#8217;s transfer agent shall (a) in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the DTC participant account nominated by the Holder through DTC&#8217;s DWAC system or (b) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if the shares of Series </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preferred stock being converted have been issued in global form eligible for book-entry settlement with DTC, the Conversion Shares shall be delivered to the Holder through book-entry transfer through the facilities of DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind any Notice of Conversion by written notice to the Corporation and its transfer agent at any time on or before its electronic receipt of such shares, as applicable, in which event the Corporation&#8217;s transfer agent shall promptly direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series&#160;A Preferred Stock unsuccessfully tendered for conversion to the Corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt;text-decoration:underline">Obligation Absolute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section&#160;6(d)(ii)&#160;above, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series&#160;A Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Nothing herein shall limit a Holder&#8217;s right to pursue actual damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief&#59; provided that Holder shall not receive duplicate damages for the Corporation&#8217;s failure to deliver Conversion Shares within the period specified herein. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section&#160;hereof or under applicable law.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Shares Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Corporation fails to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section&#160;6(d)(ii)&#160;(other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required to or otherwise purchases (in an open market transaction or otherwise), shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then the Corporation shall (A)&#160;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&#160;such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such Holder, either reissue (if surrendered) the shares of Series&#160;A Preferred Stock, equal to the number of shares of Series&#160;A Preferred Stock, submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(ii). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series&#160;A Preferred Stock,  with respect to which the actual sale price (including any brokerage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&#160;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&#160;Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver shares of Common Stock upon conversion of the shares of Series&#160;A Preferred Stock as required pursuant to the terms hereof&#59; provided, however, that the Holder shall not be entitled to both (i)&#160;require the reissuance of the shares of Series&#160;A Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&#160;receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section&#160;6(d)(ii).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Reservation of Shares Issuable Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Corporation covenants that it will at all times following receipt of the Requisite Approval reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series&#160;A Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series&#160;A Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of Section&#160;7) upon the conversion of all outstanding shares of Series&#160;A Preferred Stock. Such reservation shall comply without regard to the provisions of Section 6(f). The Corporation covenants that following receipt of the Requisite Approval all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable and free and clear of all liens and other encumbrances.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion of the Series&#160;A Preferred Stock. All fractional shares shall be rounded down to the nearest whole shares of Common Stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt;text-decoration:underline">Transfer Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The issuance of book entry notations for Conversion Shares shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such book entry notation, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such book entry notation upon conversion in a name other than that of the registered Holder(s)&#160;of such shares of Series&#160;A Preferred Stock and the Corporation shall not be required to issue or deliver such book entry notation unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Status as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon each Conversion Date in which the Series A Preferred Stock converts into Common Stock&#58; (i)&#160;the shares of Series&#160;A Preferred Stock being converted shall be deemed converted into shares of Common Stock&#59; and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series&#160;A Preferred Stock shall cease and terminate, excepting only the right to receive book entry notations for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series&#160;A Preferred Stock.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Limitations on Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as set forth in this Section 6(f), a Holder shall not have the right to convert any portion of the Series A Preferred Stock, to vote in its capacity as a holder of shares of Series A Preferred Stock with respect to matters submitted to holders of the Common Stock or take delivery of shares of Common Stock upon any automatic conversion of shares of Series A Preferred Stock, in each case, to the extent that after giving effect to such conversion, action or delivery, as applicable, such Holder (together with such Holder&#8217;s Affiliates, any other Persons acting as a group together, and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s and the other Attribution Parties for purposes of Section 13(d) of the Exchange Act (such Persons, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Attribution Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) would beneficially own in excess of 9.99% (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Maximum Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the shares of Common Stock outstanding immediately after giving effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unconverted portion of the Series A Preferred Stock beneficially owned by such Holder and its Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation beneficially owned by such Holder and its Attribution Parties (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. For purposes of this Section 6(f), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Corporation&#8217;s most recent Form 10-K, Proxy Statement, Form 10-Q, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (2) a more recent public announcement by the Corporation or (3) any other notice by the Corporation or the Corporation&#8217;s transfer agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of a Holder, where such request indicates that it is being made pursuant to this Section 6(f), the Corporation shall within one (1) Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Series A Preferred Stock, by a Holder and its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. In the event that the issuance of shares of Common Stock to the Holder upon the conversion of any of such Holder&#8217;s shares of Series A Preferred Stock results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock, the number of shares so issued by which such Holder&#8217;s and the other Attribution Parties&#8217; aggregate beneficial ownership exceeds the Maximum Percentage (the &#8220;Excess Shares&#8221;) shall be deemed null and void and shall be cancelled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ab initio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and such Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void and&#47;or any other shares of Series A Preferred Stock have been purported to be converted or mandatorily converted in excess of the limitations set forth in this Section 6(f), the Company shall return to the Holder the number of shares of Series A Preferred Stock corresponding to such excess. Upon delivery of a written notice to the Corporation, a Holder may from time to time increase or decrease the Maximum Percentage to any other percentage (not in excess of 19.99% of the issued and outstanding Common Stock </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediately after giving effect to the issuance of the Common Stock issuable upon conversion of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Series A Preferred Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if exceeding that limit would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as specified in such notice&#59; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Corporation and (ii) any such increase or decrease will apply only to such Holder and other Attribution Parties and not to any other holder of Series A Preferred Stock, provided, for the avoidance of doubt, that no such decrease shall affect the validity of any prior c</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onversion of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Series A Preferred Stock by Holder or any Attribution Party. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms hereof in excess of the Maximum Percentage shall not be deemed to be beneficially owned by a Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to convert Series A Preferred Stock pursuant to this Section 6(f) shall have any effect on the applicability of the provisions of this Section 6(f) with respect to any subsequent determination of whether Series A Preferred Stock may be converted. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(f) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 6(f) or to make changes or supplements necessary or desirable to properly give effect to such limitation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Stock Dividends and Stock Splits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Corporation, at any time while any shares of Series&#160;A Preferred Stock are outstanding&#58; (i)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock with respect to the then outstanding shares of Common Stock&#59; (ii)&#160;subdivides outstanding shares of Common Stock into a larger number of shares&#59; or (iii)&#160;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this Section&#160;7(a)&#160;shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Reclassification, Exchange or Substitution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Common Stock issuable upon the conversion of the Series A Preferred Stock shall be changed into the same or a different number of shares of any class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares or stock dividend provided for above, or a reorganization, merger, consolidation, or sale of assets provided for below), then and in each such event the holder of each such share of Series A Preferred Stock shall have the right thereafter to convert such share into the kind and amount of shares of stock and other securities and property receivable, upon such reorganization, reclassification, or other change, by holders of the number of shares of Common Stock into which such shares of Series A Preferred Stock might have been converted immediately prior to such reorganization, reclassification, or change, all subject to further adjustment as provided herein.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Merger or Reorganization, etc</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Company in which the Common Stock (but not the Series A Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">paragraphs (a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;of this&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Series A Preferred Stock shall be convertible into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Company issuable upon conversion of one share of Series A Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction (without regard to any limitation in&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;on the conversion of the Convertible Preferred Stock)&#59; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;with respect to the rights and interests thereafter of the holders of the Series A Preferred</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock to the end that the provisions set forth in this Section 7 (including provisions with respect to changes in and other adjustments of the Conversion Price, as applicable) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Series A Preferred Stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All calculations under this Section&#160;7 shall be made to the nearest cent or the nearest 1&#47;100th of a share, as the case may be. For purposes of this Section&#160;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Notice to the Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Adjustment to Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever the Conversion Price is adjusted pursuant to any provision of this Section&#160;7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If (A)&#160;the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&#160;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&#160;the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&#160;the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&#160;the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cause to be filed at each office or agency maintained for the purpose of conversion of the shares of Series&#160;A Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&#160;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&#160;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice&#59; and provided further, that in each case, the Corporation will only be required to provide such information to the Holder if such information shall have be made known to the public prior to or in conjunction with such notice being provided to the Holder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Requisite Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Corporation shall, as soon as practicable following the Issuance Date, but not more than thirty (30) days thereafter, file a preliminary proxy statement for a vote of its stockholders to approve  the issuance of all Conversion Shares in compliance with Nasdaq Listing Rule 5635(b) and&#47;or (d) and to amend the Company&#8217;s certificate of incorporation to increase the authorized number of shares of Common Stock to enable the issuance or reservation for issuance, as applicable, of all of the Conversion Shares (without regard to any limitation on conversion set forth herein) in compliance with the rules and regulations of Nasdaq (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Corporation shall, as soon as practicable following notification from the staff of the Commission that it has completed its review of the preliminary proxy statement or that it will not review the preliminary proxy statement, file and mail a definitive proxy statement for the vote of its stockholders to approve the Proposals. The Corporation covenants and agrees that its Board of Directors shall unanimously recommend that the Proposals be approved by the Corporation&#8217;s stockholders at all meetings in which such Proposals are considered and promptly file the necessary amendments to the Corporation&#8217;s certificate of incorporation after the Proposals are approved. If the Corporation&#8217;s stockholders do not approve such Proposals at the first meeting in which they are voted on by stockholders, the Corporation covenants and agrees that it will submit the Proposals for approval of the Corporation&#8217;s stockholders at least annually until such approval is obtained. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series&#160;A Preferred Stock granted hereunder may be waived as to all shares of Series&#160;A Preferred Stock (and the Holders thereof) upon the written consent of the Requisite Holders, unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be required.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Next Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Status of Converted Series&#160;A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any shares of Series&#160;A Preferred Stock shall be converted by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series&#160;A Preferred Stock.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">********************</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;&#160;&#160;&#160;</font></div></div></div><div id="i18e7a931ae3944fea7da7704d37b457f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;Cidara Therapeutics, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock to be executed by its duly authorized officer this 24th day of April, 2024.</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="margin-bottom:24pt;padding-left:234pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Jeffrey Stein, Ph.D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>Name&#58;  Jeffrey Stein, Ph.D.&#160;&#160;&#160;&#160;<br>Title&#58;   President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div style="text-indent:24.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNEX A</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTICE OF CONVERSION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(TO BE EXECUTED BY THE REGISTERED HOLDER<br>IN ORDER TO CONVERT SHARES OF SERIES A PREFERRED STOCK)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series&#160;A Preferred Stock indicated below, represented by stock certificate No(s). ____&#160;(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Preferred Stock Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), into the number of shares of Common Stock of Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;), equal to the Share Conversion Number multiplied by the number of shares of Series&#160;A Preferred Stock indicated below, provided that, to the extent such conversion would cause such Holder to exceed the Maximum Percentage (as defined in Section 6(f) of the Certificate of Designation), any shares of Series A Preferred Stock convertible into the number of shares of Common Stock that would result in the foregoing exceeding Maximum Percentage shall not convert into shares of Common Stock and such Holder shall retain any such shares of Series A Preferred Stock. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;) filed by the Corporation with the Delaware Secretary of State on April 24, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The undersigned Holder&#8217;s right to convert the shares of Series A Preferred Stock is subject to the Maximum Percentage described in Section 6(f) of the Certificate of Designation. Therefore, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with any Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock subject to this Notice of Conversion, but excluding (i) exercise of the remaining, unconverted portion of the Series A Preferred Stock beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation beneficially owned by such Person and its Attribution Parties (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein, is&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conversion calculations&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date to Effect Conversion&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of shares of Series&#160;A Preferred Stock owned prior to Conversion&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of shares of Series&#160;A Preferred Stock to be Converted&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of shares of Common Stock to be Issued&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Address for delivery of physical certificates&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Or</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">for DWAC Delivery&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DWAC Instructions&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Broker no&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Account no&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HOLDER&#58;</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br>Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br>Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;____________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exhibit1012024-04x24.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9a0407bc8d95489ba95e50971d54402a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">EXECUTION VERSION</font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECURITIES PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Securities Purchase Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is dated as of April 23, 2024, by and among Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and assigns, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Rule 506 of Regulation D (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as promulgated by the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the Securities Act.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, that aggregate number of shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), set forth below such Purchaser&#8217;s name on the signature page of this Agreement (which aggregate amount for all Purchasers together shall be 240,000 shares of Series A Preferred Stock and shall be collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the Certificate of Designation of the Series A Convertible Preferred Stock, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), each Share is convertible into shares of common stock, par value $0.0001 per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The shares of Common Stock issuable upon conversion of the Shares are referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Shares and the Conversion Shares collectively are referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.45pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquiring Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation pending or, to the Company&#8217;s Knowledge, threatened in writing against the Company, any Subsidiary or any of their respective properties or any officer, director or employee of the Company or any Subsidiary acting in his or her capacity as an officer, director or employee before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency, regulatory authority, stock market, stock exchange or trading facility.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Advance Indemnification Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">BCLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means entities affiliated with Bain Capital Life Sciences Investors, LLC. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Block Trade</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an offering and&#47;or sale of Registrable Securities by any Purchasers on a block trade or underwritten basis (whether firm commitment or otherwise) without substantial marketing efforts prior to pricing, including, without limitation, a same day trade, overnight trade or similar transaction and without a lock-up agreement of more than forty-five (45) days to which the Company is a party (including, for the avoidance of doubt, any lock-up or clear market covenant contained in the underwriting agreement for such transaction). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the board of directors of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the closing of the purchase and sale of the Shares pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof are satisfied or waived, as the case may be, or such other date as the parties may agree.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals, and also includes any other class of securities into which the Common Stock may hereafter be reclassified or changed into. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any securities of the Company or any Subsidiary which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock or other securities that entitle the holder to receive, directly or indirectly, Common Stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cooley  LLP, with offices located at 10265 Science Center Drive,  San Diego, California 92121.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Covered Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Company as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company&#8217;s Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means with respect to any statement made to the Company&#8217;s Knowledge, that the statement is based upon the actual knowledge of the executive officers of the Company having responsibility for the matter or matters that are the subject of the statement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cut Back Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Effectiveness Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(cc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Exempt Issuance&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means (a) the issuance of shares of Common Stock, options to purchase shares of Common Stock or other Related Securities (as defined below), or shares of Common Stock upon exercise, conversion, or vesting and settlement of options or other Related Securities, as the case may be, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the SEC Reports, (b) the issuance of shares of Common Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants outstanding on the date hereof and described in the SEC Reports, provided that such securities have not been amended since the date hereof to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) the filing of a registration statement on Form S-8 to register shares of Common Stock issuable pursuant to the terms of a stock option, stock bonus or other stock plan or arrangement described in the SEC Reports, (d) facilitating the establishment of a trading plan on behalf of a stockholder, officer or director of the Company pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, (e) issuance of shares of Common Stock in connection with any joint venture, commercial or collaborative relationship or the acquisition or license by the Company of the securities, businesses, property or other assets of another person or entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition&#59; provided, however, that in the case of this clause (e), the sum of the aggregate number of shares </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of common stock of the Company so issued shall not exceed 750,000 Shares, and  (f) issuance of shares of Common Stock upon the exercise or exchange of or conversion of any Securities issued hereunder. For purposes of the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Related Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any options or warrants or other rights to acquire shares of Common Stock or any securities exchangeable or exercisable for or convertible into shares of Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, shares of Common Stock. Notwithstanding anything to the contrary contained in this paragraph, the Company shall be permitted to keep in effect the Controlled Equity Offering Sales Agreement, dated November 8, 2018, by and between the Company and Cantor Fitzgerald &#38; Co., provided that no sales of securities shall be made under such Controlled Equity Offering Sales Agreement during the period set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Expected Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means April 24, 2024.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Filing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(ee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means U.S. generally accepted accounting principles, as applied by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private)&#59; (ii) any self-regulatory organization&#59; or (iii) any political subdivision of any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(cc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Irrevocable Transfer Agent Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Janssen License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the License and Technology Transfer Agreement, dated on or about the date hereof, by and between the Company and Janssen Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Legend Removal Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Liquidated Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a material adverse effect on the results of operations, assets, prospects, business or financial condition of the Company and the Subsidiaries, taken as a whole, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">except that any of the following, either alone or in combination, shall not be deemed a Material Adverse Effect&#58; (i)&#160;effects caused by changes or circumstances affecting general market conditions in the U.S. economy or which are generally applicable to the industry in which the Company operates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such effects are not borne disproportionately by the Company, (ii)&#160;effects resulting from or relating to the announcement or disclosure of the sale of the Securities or other transactions contemplated by this Agreement, or (iii)&#160;effects caused by any event, occurrence or condition resulting from or relating to the taking of any action in accordance with this Agreement. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any contract of the Company that has been filed or was required to have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(2), Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Material Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Maximum Threshold&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Minimum Takedown Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the state and federal courts sitting in the City of New York, Borough of Manhattan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Net Short Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(ff)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the fifth (5th) Business Day following the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Pool Increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Principal Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Trading Market on which the Common Stock is primarily listed and quoted for trading, which, as of the date of this Agreement and the Closing Date, shall be The Nasdaq Capital Market.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means $1,000 per Share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">RA Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means RA Capital Healthcare Fund, L.P. and affiliated funds. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Registrable Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all Conversion Shares without taking into account any limitations upon conversion set forth in the Certificate of Designation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that a security shall cease to be a Registrable Share upon the earliest to occur of the following&#58; (a) a Registration Statement registering such security under the Securities Act has been declared or becomes effective and such security has been sold or otherwise transferred by the holder thereof pursuant to and in a manner contemplated by such effective Registration Statement, (b) such security is sold pursuant to Rule 144 under circumstances in which any legend borne by such security relating to restrictions on transferability thereof, under the Securities Act or otherwise, is removed by the Company, (c) such security is eligible to be sold pursuant to Rule 144 without any limitation as to volume of sales and without the holder complying with any method of sale requirements or notice requirements under Rule 144, or (d) such security shall cease to be outstanding following its issuance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Required Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Registration Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a registration statement or registration statements of the Company filed under the Securities Act pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration statements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Restriction Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sale Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sanctioned Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, a country, region or territory which is itself the subject or target of any Sanctions (at the time of this Agreement, the so-called Donetsk People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, the Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, (a)&#160;any Person listed in any Sanctions-related list of designated Persons, (b)&#160;any Person operating, organized or resident in a Sanctioned Country, (c)&#160;any Person owned or controlled by any such Person or Persons described in the foregoing clauses&#160;(a) or (b), or (d)&#160;any Person otherwise the subject or target of any Sanctions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S.&#160;Department of State or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) the United Nations Security Council, the European Union, any European Union member state, His Majesty&#8217;s Treasury of the United Kingdom or other relevant sanctions authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">SEC Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s&#8221; means reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material, including (a) the exhibits thereto and documents incorporated by reference therein and (b) Current Reports on Form 8-K to be filed on or about the Closing Date in substantially the forms provided to Purchasers prior to the Signing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">SEC Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4.15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(a)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Recitals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Short Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; include, without limitation, (a) all &#8220;short sales&#8221; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, &#8220;put equivalent positions&#8221; (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (b) sales and other transactions through non-U.S. broker dealers or foreign regulated brokers (but shall not be deemed to include the location and&#47;or reservation of borrowable shares of Common Stock).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means April 23, 2024.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Staff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the staff of the Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Standard Settlement Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the standard settlement period, expressed in a number of Trading Days, for the Company&#8217;s primary trading market or quotation system with respect to the Common Stock that is in effect on such date, which as of the date hereof is &#8220;T+2.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Stock Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Subscription Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Purchaser, the aggregate amount to be paid for the Shares purchased hereunder as indicated on such Purchaser&#8217;s signature page to this Agreement next to the heading &#8220;Aggregate Purchase Price (Subscription Amount)&#8221; in United States dollars and in immediately available funds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any subsidiary of the Company listed in the SEC Reports, and shall, where applicable, include any subsidiary of the Company formed or acquired after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Support Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain support agreement, dated the date hereof, by and among the Company and each of Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Biotechnology Value Trading Fund OS LP, MSI BVF SPV, LLC, Investment 10, L.L.C. and Company&#8217;s directors and executive officers, in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all federal, state, local, non-U.S. and other taxes, charges, fees, duties, levies, imposts, customs or other assessments, including all net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, profit share, license, lease, service, service use, value added, withholding, payroll, employment, excise, estimated, severance, stamp, occupation, premium, real property, personal property, payroll, escheat, unclaimed property, windfall profits, environmental, capital stock, social security (or similar), unemployment, disability, registration, alternative or add-on minimum, estimated, or other taxes, fees, assessments, customs, duties, levies, imposts or charges of any kind whatsoever, whether disputed or not,  together with any interest, penalties, additions to tax, fines or other additional amounts imposed thereon or related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Tax Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any return, statement, schedule, declaration, claim for refund, report, document or form filed or required to be filed with respect to Taxes, including any amendment, attachment and supplement thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Trading Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by OTC Markets Group Inc. (formerly OTC Markets Inc.) (or any similar organization or agency succeeding to its functions of reporting prices)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means whichever of the New York Stock Exchange, the American Stock Exchange, The Nasdaq Global Select Market, The Nasdaq Global Market, The Nasdaq Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means this Agreement, the schedules and exhibits attached hereto, the Certificate of Designation, the Irrevocable Transfer Agent Instructions, the Support Agreement and any other documents or agreements explicitly contemplated hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 55 Challenger Road, Ridgefield Park, New Jersey 07660, or any successor transfer agent for the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Shelf Takedown</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Withdrawal Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.79pt"><br>PURCHASE AND SALE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number of shares of Series A Preferred Stock equal to the quotient resulting from dividing (i) the Subscription Amount for such Purchaser by (ii) the Purchase Price, rounded down to the nearest whole Share, which shall be equal to the number of Shares such Purchaser is purchasing as is set forth on such Purchaser&#8217;s signature page to this Agreement next to the heading &#8220;Number of Shares to be Acquired,&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Closing of the purchase and sale of the Shares shall take place at the offices of Company Counsel on the Closing Date or at such other locations or remotely by facsimile transmission or other electronic means as the parties may mutually agree.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on the Signing Date, each Purchaser shall wire its Subscription Amount, in United States dollars and in immediately available funds, to an account established by the Company. On the Closing Date, the Company shall irrevocably instruct the Transfer Agent to deliver to each Purchaser book-entry statements, free and clear of all restrictive and other legends (except as expressly provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof), evidencing the number of Shares such Purchaser is purchasing as is set forth on such Purchaser&#8217;s signature page to this Agreement next to the heading &#8220;Number of Shares to be Acquired,&#8221; within two (2) Trading Days of the Closing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Closing Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser the following (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">this Agreement, duly executed by the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">facsimile or other electronic copies of one or more book-entry statements from the Transfer Agent, free and clear of all restrictive and other legends (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof), evidencing the Shares subscribed for by such Purchaser hereunder, registered in the name of such Purchaser as set forth on the Book Entry Questionnaire included as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Book-Entry Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.53pt">a legal opinion of Company Counsel, dated as of the Closing Date, executed by such counsel and addressed to the Purchasers, in a form reasonably acceptable to the such parties&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">the Certificate of Designation shall have been filed with the Secretary of State of Delaware, which Certificate of Designation shall continue to be in full force and effect as of the Closing Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, the book-entry statements evidencing a number of Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Purchase Price, registered in the name of such Purchaser&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">a certificate of the Secretary of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), dated as of the Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving the transactions contemplated by this Agreement and the other Transaction Documents, the filing of the Certificate of Designation and the issuance of the Securities, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) certifying the current versions of the certificate of incorporation, as amended, the Certificate of Designation and by-laws of the Company and (c) certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.08pt">the Compliance Certificate referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.03pt">a certificate evidencing the formation and good standing of the Company issued by the Secretary of State (or comparable office) of the State of Delaware, as of a date within three (3) Business Days of the Closing Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">a certificate evidencing the Company&#8217;s qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company is qualified to do business as a foreign corporation, as of a date within three (3) Business Days of the Closing Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">a certified copy of the certificate of incorporation and Certificate of Designation, each as certified by the Secretary of State (or comparable office) of the State of Delaware, as of a date within four (4) Business Days of the Closing Date&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">the Support Agreements duly executed by the Company and all parties thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">this Agreement, duly executed by such Purchaser&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">its Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth as the &#8220;Purchase Price&#8221; indicated below such Purchaser&#8217;s name on the applicable signature page hereto under the heading &#8220;Aggregate Purchase Price (Subscription Amount)&#8221; by wire transfer to the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.53pt">a fully completed and duly executed Accredited Investor Questionnaire, satisfactory to the Company, and Book Entry Questionnaire in the forms attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits B-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, respectively&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">an Internal Revenue Service Form W-9 (or any successor form or applicable Form W-8 in the case of a Purchaser that is not a U.S. person), duly and validly executed by such Purchaser (or its nominee in accordance with the Purchaser&#8217;s delivery instructions).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event the Closing does not occur within three (3) Business Days after the Expected Closing Date (a) the Company shall promptly, upon a Purchaser&#8217;s written request (but no later than one (1) Business Day thereafter), return the Subscription Amount funded to the Company by such Purchaser by wire transfer in United States dollars and in immediately available funds to the account specified by such Purchaser, and (b) any the book-entry statements evidencing the Shares purchased by such Purchaser shall be deemed cancelled&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, unless this Agreement has been terminated pursuant to&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;hereof, such return of funds shall not terminate this Agreement or relieve the Company of its obligations to issue and sell, or of each Purchaser to purchase the Shares at the Closing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company shall not be obligated to issue and sell the Shares to each Purchaser unless such Purchaser </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">had paid the applicable Subscription Amount pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, at which time the Shares shall be issued.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.13pt"><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date), to each of the Purchasers&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company has no direct or indirect Subsidiaries other than those listed in the SEC Reports. Each of the Subsidiaries has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business. Each of the Subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Incorporation and Good Standing of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as currently conducted and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of California and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Authorization&#59; Enforcement&#59; Validity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The Company&#8217;s execution and delivery of each of the Transaction Documents to which it is a party and the consummation by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares and the Conversion Shares) have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate action is required by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with the Stockholder Approval and the Required Approvals. Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies or by other equitable principles of general application, (ii) as limited by laws relating to the availability of specific performance, injunctive </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of the Shares and the Conversion Shares) do not and will not (i) conflict with or violate any provisions of the Company&#8217;s or any Subsidiary&#8217;s certificate of incorporation, bylaws or otherwise result in a violation of the organizational documents of the Company, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would result in a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company or a Subsidiary is bound or affected, except in the case of clauses (ii) and (iii) such as would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Filings, Consents and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor any of its Subsidiaries is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including the issuance of the Securities), other than (i) the filing with the Commission of one or more Registration Statements in accordance with the requirements hereof, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and&#47;or application(s) to the Principal Trading Market for the issuance and sale of the Securities and the listing of the Conversion Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, (vi) approval of the Transaction Proposals by the stockholders of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (vii) those that have been made or obtained prior to the date of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Required Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of the Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights. The Conversion Shares issuable upon conversion of the Shares have been duly authorized and, when issued in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights. Assuming the accuracy of the representations and warranties of the Purchasers in this Agreement, the Securities will be issued in compliance with all applicable federal and state securities laws. Following the Stockholder Approval, the Company shall have reserved from its duly authorized capital stock the maximum number of Conversion Shares issuable upon conversion of the Shares. The Company shall, following the Stockholder Approval and so long as any of the Shares are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Shares, the maximum number of shares of Common Stock </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">issuable upon the exercise or conversion thereof (without taking into account any limitations set forth in the Certificate of Designation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The authorized, issued and outstanding capital stock of the Company as disclosed in its most recent SEC Report containing such disclosure was accurate in all material respects as of the date indicated in such SEC Report. The Company has not issued any capital stock since the date of its most recently filed SEC Report other than to reflect stock option and warrant exercises that do not, individually or in the aggregate, have a material effect on the issued and outstanding capital stock, options and other securities. All of the issued and outstanding shares of capital stock of the Company  have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the issued and outstanding shares of the Company were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. Except as disclosed in the SEC Reports or as provided in any of the Transaction Documents, there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its Subsidiaries and other than equity awards subsequently issued pursuant to employee benefit plans. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents that have not been effectively waived as of the Closing Date. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">SEC Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the Company has filed all SEC Reports on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension, except where the failure to file on a timely basis would not have or reasonably be expected to result in a Material Adverse Effect (including, for this purpose only, any failure which would prevent any Purchaser from using Rule&#160;144 to resell any Securities). As of their respective filing dates, or to the extent corrected by a subsequent restatement, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. Each of the Material Contracts to which the Company or any Subsidiary is a party or to which the property or assets of the Company or any of its Subsidiaries are subject has been filed as an exhibit to the SEC Reports.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement). Such financial statements have been prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries taken as a whole as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial year-end audit adjustments. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Material Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there have been no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered materially its method of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company), and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock issued in the ordinary course as dividends on outstanding preferred stock or issued pursuant to existing Company stock option or stock purchase plans or executive and director compensation arrangements disclosed in the SEC Reports. Except for the issuance of the Shares and the transactions contemplated by the Transaction Documents, no event, liability or development has occurred or exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made that has not been publicly disclosed as of the date that this representation is made. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) except as specifically disclosed in the SEC Reports, would, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the Company&#8217;s Knowledge any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company&#8217;s Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any of its Subsidiaries under the Exchange Act or the Securities Act. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Employment Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company or its subsidiaries, exists or, to the Company&#8217;s Knowledge, is threatened or imminent, which could reasonably be expected to result in a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor any of its Subsidiaries (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries under), nor has the Company or any of its Subsidiaries received written notice of a claim that it is in default under or that it is in violation of, any Material Contract (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body having jurisdiction over the Company or its properties or assets, or (iii) is in violation of, or in receipt of written notice that it is in violation of, any statute, rule or regulation of any governmental authority applicable to the Company, except in each case as would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company and its Subsidiaries possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">bodies to conduct their respective business as currently conducted and as described in the SEC Reports (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Material Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except where the failure to so possess would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation of, or in default under, any of the Material Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit, except where failure to be so in compliance would not be expected, individually or in the aggregate, to have a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Title to Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company and its Subsidiaries possess good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 3.1(i) above (or elsewhere in the SEC Reports), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The real property, improvements, equipment and personal property held under lease by the Company are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company and each of its Subsidiaries owns, possesses or has valid and enforceable licenses or other rights to use, or can acquire on reasonable terms, all Intellectual Property (as defined below) necessary for the conduct of the Company&#8217;s and its Subsidiaries&#8217; business as now conducted or as described in the SEC Reports to be conducted or as otherwise contemplated to be conducted as of the Closing Date, including without limitation for the development, manufacture and commercialization of compounds and product candidates subject to the Janssen License Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company Product Candidates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Furthermore, (A) to the Company&#8217;s Knowledge, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property&#59; (B) there is no pending or, to the Company&#8217;s Knowledge, threatened, action, suit, proceeding or claim by others challenging the Company&#8217;s or any of its Subsidiaries&#8217; rights in or to any such Intellectual Property and, to Company&#8217;s Knowledge, there is no basis for such claim&#59; (C) the Intellectual Property owned by the Company and its Subsidiaries, and to the Company&#8217;s Knowledge, the Intellectual Property licensed to the Company and its Subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the Company&#8217;s Knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability or scope of any such Intellectual Property&#59; and to Company&#8217;s Knowledge, all issued patents within such Intellectual Property are valid and enforceable&#59; (D) there is no pending or, to the Company&#8217;s Knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its Subsidiaries, or the development, manufacture and commercialization of the Company Product Candidates, infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and neither the Company or any of its Subsidiaries has received any written notice of such claim or has Knowledge of any basis for such a claim&#59; and (E) to the Company&#8217;s Knowledge, no employee of the Company or any of its Subsidiaries is in or has ever been in material violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#8217;s employment with the Company or any of its Subsidiaries or actions undertaken by the employee while employed with the Company or any of its Subsidiaries.  The Company and its Subsidiaries have a written agreement in place with each of its employees and contractors, which (x) assigns to the Company or such Subsidiary all rights, title and interest in and to all inventions and Intellectual Property developed by such employee or contractor in the course of such employment or otherwise conducting activities on behalf of the Company or such Subsidiary and (y) subjects such employee or contractor to reasonable obligations of confidentiality, non-disclosure and non-use with respect to all confidential information of the Company and its Subsidiaries.  To </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Company&#8217;s Knowledge, no employee or contractor of the Company or its Affiliates is in material violation of any such agreement.  The Company and its Subsidiaries have employed reasonable efforts to maintain the confidentiality of any and all trade secrets within such Intellectual Property. The Company and each Subsidiary and, to the Company&#8217;s Knowledge, each counterparty thereto has complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its Subsidiary, and all such agreements are in full force and effect. The Company Product Candidates fall within the scope of the claims of one or more patents or applications owned by, or exclusively licensed to, the Company or the applicable Subsidiary. &#8220;Intellectual Property&#8221; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, know-how and other intellectual property. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Company and its Subsidiaries are insured by financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for companies of similar size, engaged in similar businesses in similar industries including, but not limited to, policies covering real and personal property owned or leased by the Company and its Subsidiaries against theft, damage, destruction, and acts of vandalism and policies covering the Company and its Subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its Subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries have been denied any insurance coverage which it has sought or for which it has applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions With Affiliates and Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the Company&#8217;s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), that would be required to be disclosed pursuant to Rule 404 of Regulation S-K promulgated under the Securities Act that has not otherwise been appropriately disclosed in accordance with the Exchange Act. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.4pt;text-decoration:underline">Internal Accounting Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the Company makes and keeps accurate books and records and maintains a system of internal accounting controls designed, and which the Company believes is sufficient to provide reasonable assurance that&#58; (i) transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s principal executive officer and its principal financial officer by others within the Company and its consolidated subsidiaries&#59; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company&#8217;s most recent fiscal quarter&#59; and (iii) are effective in all material respects to perform the functions for which they were established. Except as disclosed in the SEC Reports, since the end of the Company&#8217;s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. Except as disclosed in the SEC Reports, the Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Certain Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company with respect to the offer and sale of the Shares. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 3.1(t) that may be due in connection with the transactions contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each Purchaser harmless against, any liability, loss or expense (including, without limitation, attorneys&#8217; fees and out-of-pocket expenses) arising in connection with any such right, interest or claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement and the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction Documents. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.74pt;text-decoration:underline">Investment Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The Company is not, and immediately after receipt of payment for the Shares, will not be or be an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act of 1940, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Other than each of the Purchasers pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof,  no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company other than those securities which are currently registered on an effective registration statement on file with the Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Listing and Maintenance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company&#8217;s Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Company has not, in the twelve (12) months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Application of Takeover Protections&#59; Rights Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#8217;s charter documents or the laws of its state of incorporation that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation, the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.92pt;text-decoration:underline">No Integrated Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, none of the Company, its Subsidiaries nor, to the Company&#8217;s Knowledge, any of its Affiliates or any Person acting on its behalf has, directly or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market on which any of the securities of the Company are listed or designated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as disclosed in the SEC Reports, the Company and its Subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns that have come due or has properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against it except as may be being contested in good faith and by appropriate proceedings, except where the failure to so file or pay would not reasonably be expected to have a Material Adverse Effect. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 3.1(i) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its Subsidiaries is being contested or has not otherwise been finally determined, except as would not reasonably be expected to have a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.92pt;text-decoration:underline">Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#58; (i) neither the Company nor any of its Subsidiaries are in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements&#59; (iii) there are no pending or, to the Company&#8217;s Knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its Subsidiaries&#59; and (iv) to the Company&#8217;s Knowledge, there are no events or circumstances, existing as of the date hereof, that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental Laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">No General Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor, to the Company&#8217;s Knowledge, any person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.92pt;text-decoration:underline">Foreign Corrupt Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor any of its Subsidiaries nor any director, officer, employee, nor, to the Company&#8217;s Knowledge, any agent, affiliate or other person acting on behalf of the Company or its Subsidiaries have, in the course of its actions for, or on behalf of, the Company or its Subsidiaries (i) made any unlawful contribution, gift, entertainment or other unlawful expenses relating </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to political activity&#59; (ii) made any direct or indirect unlawful payment to any domestic government official, &#8220;foreign official&#8221; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or employee&#59; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation&#59; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or employee&#59; and the Company, its Subsidiaries and, to the Company&#8217;s Knowledge, the Company&#8217;s and such Subsidiaries&#8217; affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.14pt;text-decoration:underline">Off Balance Sheet Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There are no transactions, arrangements and other relationships between and&#47;or among the Company, and&#47;or, to the Company&#8217;s Knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that could reasonably be expected to affect materially the Company&#8217;s liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described in the Commission&#8217;s Statement about Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056&#59; 34-45321&#59; FR-61), required to be described in the SEC Reports which have not been described as required. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">Acknowledgment Regarding Purchasers&#8217; Purchase of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.&#160;The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities.&#160;The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">Regulation M Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;The Company has not, and to the Company&#8217;s Knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the securities of the Company or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.75pt;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor any Subsidiary nor, to the Company&#8217;s Knowledge, any director, officer, agent, employee, Affiliate or Person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department&#59; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person or entity, for the purpose of financing or facilitating any activities, business or transaction with any Sanctioned Person or in any Sanctioned Country or in any manner that would result in the violation of any Sanctions applicable to any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.75pt;text-decoration:underline">No Bad Actors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disqualification Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is applicable to the Company or, to the Company&#8217;s </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Knowledge, any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii&#8211;iv) or (d)(3) is applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;The Company and each of its subsidiaries have such permits, licenses, patents, franchises, certificates of need and other approvals, consents and other authorizations issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including, without limitation, any Investigational New Drug Application (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and&#47;or New Drug Application (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as required by the U.S. Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), any authorizations issued by the Drug Enforcement Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or any other authorizations issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of pharmaceuticals such as those being developed by the Company and its subsidiaries (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect&#59; the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits are valid and in full force and effect&#59; the Company has not received any notice of proceedings relating to the revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect&#59; the Company has not failed to submit to the FDA any IND or NDA necessary to conduct the business of the Company, any such filings that were required to be made were in material compliance with applicable Laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such filings or submissions that were made. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.75pt;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Company nor any of its subsidiaries has failed to file with the applicable regulatory authorities (including, without limitation, the FDA, or any foreign, federal, state, provincial or local governmental or regulatory authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not have a Material Adverse Effect&#59; except as disclosed in the SEC Reports, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable Laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not have a Material Adverse Effect. The Company has operated and currently is, in all material respects, in compliance with the FDCA (as defined below) and all applicable rules and regulations of other federal, state, local and foreign governmental bodies exercising comparable authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.25pt;text-decoration:underline">Compliance with Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Company and its Subsidiaries is, and at all times has been, in compliance in all material respects with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this Agreement, &#8220;Health Care Laws&#8221; means&#58; (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.) and the regulations promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. &#167; 1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">statutes&#59; (iii) Medicare (Title XVIII of the Social Security Act)&#59; (iv) Medicaid (Title XIX of the Social Security Act)&#59; (v) the Controlled Substances Act (21 U.S.C. &#167;&#167; 801 et seq.) and the regulations promulgated thereunder&#59; and (vi) any and all other applicable health care laws and regulations. Neither the Company nor, to the Company&#8217;s Knowledge, any Subsidiary has received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the Company&#8217;s Knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company nor, to the Company&#8217;s Knowledge, any Subsidiary is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the Company&#8217;s Knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">Preclinical and Clinical Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The studies, tests and preclinical and clinical investigations conducted by or on behalf of the Company and its Subsidiaries were and, if still pending, are, in all material respects, being conducted in accordance with established protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable laws and authorizations, including, without limitation, the FDCA and implementing regulations including good laboratory practice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) regulations (21 C.F.R. Part 58) if any such studies, tests or preclinical and clinical investigations are being or have been conducted pursuant to GLP, and good clinical practice and IND requirements (21 C.F.R. Parts 50, 54, 56, and 312) if any such studies, tests or preclinical and clinical investigations were or are subject to good clinical practice regulations or were or are being conducted under an IND&#59; the descriptions of the results of such studies, tests and trials contained in the SEC Reports are accurate in all material respects and fairly present the data derived from such studies, tests and trials&#59; except to the extent disclosed in the SEC Reports, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question in any material respect, the study, test, or trial results described or referred to in the SEC Reports when viewed in the context in which such results are described and the clinical state of development&#59; and neither the Company nor any of its Subsidiaries have received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical investigations conducted by or on behalf of the Company or any of its Subsidiaries, except for material modifications reflected in protocol amendments to clinical and preclinical trials arising from joint discussions with such Governmental Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.3pt;text-decoration:underline">No Additional Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company does not have any agreement or understanding with any Purchaser with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Representations and Warranties of the Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the Company as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Organization&#59; Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser is an entity validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and performance by such Purchaser of the transactions </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation, such partnership, limited liability company or other applicable like action, on the part of such Purchaser. Each Transaction document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies or by other equitable principles of general application.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by such Purchaser of this Agreement and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Investment Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser understands that the Securities are &#8220;restricted securities&#8221; and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Shares and will acquire the Conversion Shares (upon conversion of the Shares) as principal for its own account and not with a view to, or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities laws, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that by making the representations herein, such Purchaser does not agree to hold any of the Securities for any minimum period of time and reserves the right, subject to the provisions of this Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to an effective registration statement under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws. Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person or entity&#59; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Purchaser Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. At the time such Purchaser was offered the Shares, it was, and at the date hereof it is, an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">General Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general advertisement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Access to Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser acknowledges that it has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities&#59; (ii) access to information about the Company and the Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment&#59; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that is necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser&#8217;s right to rely on the truth, accuracy and completeness of the SEC Reports and the Company&#8217;s representations and warranties contained in the Transaction Documents. Such Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition of the Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Trading Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Other than with respect to the transactions contemplated herein, since the time that such Purchaser was first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither the Purchaser nor any Affiliate of such Purchaser which (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to such Purchaser&#8217;s investments or trading or information concerning such Purchaser&#8217;s investments, including in respect of the Securities, and (z) is subject to such Purchaser&#8217;s review or input concerning such Affiliate&#8217;s investments or trading (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Trading Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s&#8221;) has directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser or Trading Affiliate, effected or agreed to effect any purchases or sales of the securities of the Company (including, without limitation, any Short Sales involving the Company&#8217;s securities). Notwithstanding the foregoing, in the case of a Purchaser and&#47;or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s or Trading Affiliate&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s or Trading Affiliate&#8217;s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect short sales or similar transactions in the future.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Brokers and Finders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Purchaser.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Independent Investment Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser&#8217;s business and&#47;or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. Such Purchaser confirms that none of such Persons has made any representations or warranties to such Purchaser in connection with the transactions contemplated by the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Reliance on Exemptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The purchase by such Purchaser of the Shares issuable to it at the Closing will not result in such Purchaser (individually or together with any other Person with whom such Purchaser has identified, or will have identified, itself as part of a &#8220;group&#8221; in a public filing made with the Commission involving the Company&#8217;s securities) acquiring, or obtaining the right to acquire, in excess of 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that assumes that such Closing shall have occurred. Such Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired, or obtained the right to acquire, as a result of such Closing (when added to any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that assumes that the Closing shall have occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Residency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser&#8217;s residence (if an individual) or offices in which its investment decision with respect to the Securities was made (if an entity) are located at the notice address below such Purchaser&#8217;s name on its signature page hereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company and each of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.51pt"><br>OTHER AGREEMENTS OF THE PARTIES</font></div><div style="margin-bottom:12pt;padding-left:13.5pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each Purchaser covenants that the Securities may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Securities other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Purchaser provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities may be sold pursuant to such rule) or (iv) in connection with a bona fide pledge as contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of a transfer other than pursuant to (i) through (iv) above, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights of a Purchaser under this Agreement with respect to such transferred Securities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Certificates, including, if applicable, book entry statements with the Transfer Agent, evidencing the Securities shall bear any legend as required by the &#8220;blue sky&#8221; laws of any state and a restrictive legend in substantially the following form, until such time as they are not required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:50.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR APPLICABLE STATE SECURITIES LAWS. THE </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:50.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECURITIES AND THE SECURITIES ISSUABLE UPON CONVERSION OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company acknowledges and agrees that a Purchaser may from time to time pledge, and&#47;or grant a security interest in, some or all of the legended Securities in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan. Such a pledge would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection with a subsequent transfer or foreclosure following default by the Purchaser transferee of the pledge. No notice shall be required of such pledge, but Purchaser&#8217;s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure. Each Purchaser acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Securities or for any agreement, understanding or arrangement between any Purchaser and its pledgee or secured party. At the appropriate Purchaser&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including the preparation and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders thereunder. Each Purchaser acknowledges and agrees that, except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, any Securities subject to a pledge or security interest as contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall continue to bear the legend set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and be subject to the restrictions on transfer set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Removal of Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The legend set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above shall be removed and the Company shall cause its Transfer Agent to issue book entry statements without such legend or any other legend to the holder of the applicable Securities upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account at the Depository Trust Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">DTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), if (i) such Securities are sold or transferred pursuant to the effective registration statement registering the Securities for resale (during such time that such registration statement is effective and not withdrawn or suspended, and only as permitted by such registration statement) or Rule 144 (if the transferor is not an Affiliate of the Company), or (ii) such Securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Following the earlier of (A) one year from the Closing Date or (B) Rule 144 becoming available for the resale of Securities, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions, upon request of a Purchaser, the Company shall cause Company Counsel to issue to the Transfer Agent the legal opinion referred to in the Irrevocable Transfer Agent Instructions. Any fees (with respect to the Transfer Agent, Company Counsel or otherwise) </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">associated with the issuance of such opinion or the removal of such legend shall be borne by the Company. Following such time as a legend is no longer required for certain Securities, the Company will no later than the number of Trading Days comprising the Standard Settlement Period following the delivery by a Purchaser to the Company (with notice to the Company) of a legended book entry statement representing Conversion Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and&#47;or transfer) (such Trading Day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Legend Removal Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), deliver or cause to be delivered via DTC to such Purchaser such Securities that are free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Electronic certificates for Conversion Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Purchasers by crediting the account of the Purchaser&#8217;s prime broker with DTC as directed by such Purchaser.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Irrevocable Transfer Agent Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160; The Company shall issue irrevocable instructions to its transfer agent, and any subsequent transfer agent, in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Irrevocable Transfer Agent Instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or instructions that are consistent therewith) will be given by the Company to its transfer agent in connection with this Agreement, and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will cause irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that a Purchaser shall be entitled, in addition to all other available remedies, to an order and&#47;or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Purchaser hereunder acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Securities or any interest therein without complying with the requirements of the Securities Act. While the Registration Statement remains effective, each Purchaser hereunder may sell the Conversion Shares in accordance with the plan of distribution contained in the Registration Statement and if it does so it will comply therewith and with the related prospectus delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other Purchasers, agrees that if it is notified by the Company in writing at any time that the Registration Statement registering the resale of the Conversion Shares is not effective or that the prospectus included in such Registration Statement no longer complies with the requirements of Section 10 of the Securities Act, the Purchaser will refrain from selling such Conversion Shares until such time as the Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell such Conversion Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Company shall fail for any reason or for no reason to issue via DTC to a Purchaser Securities that are free from all restrictive and other legends within the number of Trading Days comprising the Standard Settlement Period following receipt of all documents necessary for the removal of the legend set forth above, then, in addition to all other remedies available to such Purchaser, if on or after the Trading Day immediately following such Standard Settlement Period, such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the holder of shares of Common Stock that such Purchaser anticipated receiving from the Company without any restrictive legend (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Company shall, within four (4) Trading Days after such Purchaser&#8217;s </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">request and in such Purchaser&#8217;s sole discretion, (A) pay in cash to such Purchaser the amount by which (x) such Purchaser&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Purchaser was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Purchaser, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion or deliver to such Purchaser the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Purchaser shall provide the Company written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Purchaser in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit a Purchaser&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon conversion of the shares of Series A Preferred Stock as required pursuant to the terms hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Purchaser shall not be entitled to both (i) require the reissuance of the shares of Series A Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reservation of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon obtaining approval of the Transaction Proposals by the Company&#8217;s stockholders, the Company shall take all action necessary to at all times have authorized and reserved for the purpose of issuance from and after the Closing Date, for so long as any of the Shares are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Shares, the maximum number of shares of Common Stock issuable upon the exercise or conversion thereof (without taking into account any limitations set forth in the Certificate of Designation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Furnishing of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In order to enable the Purchasers to sell the Securities under Rule 144, for a period of twelve (12) months from the Closing, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. During such twelve (12) month period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Securities Laws Disclosure&#59; Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. By 9&#58;00 A.M., New York City time, on the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Trading Day immediately following the date hereof, the Company shall issue a press release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) reasonably acceptable to the Purchasers disclosing all material terms of the transactions contemplated hereby. On or before 9&#58;00 A.M., New York City time, on the second (2nd) Trading Day </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the material Transaction Documents (including, without limitation, this Agreement, the Certificate of Designation, and the Support Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, such consent not to be unreasonably withheld, except (i) as required by federal securities law in connection with (A) any registration statement contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto and (B) the filing of final Transaction Documents (including signature pages thereto) with the Commission and (ii) to the extent such disclosure is required by law, request of the Staff or Trading Market regulations, in which case the Company shall provide the Purchasers with prior written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received from the Company, any Subsidiary or any of their respective officers, directors, employees or agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are required to be publicly disclosed by the Company as described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any disclosure may be made by the Purchaser solely on a need-to-know basis to the Purchaser&#8217;s representatives or agents (including, but not limited to, such Purchaser&#8217;s legal, tax and investment advisors) that are bound by obligations of confidentiality and restrictions against disclosure of any confidential information. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Shareholder Rights Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquiring Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, in either case solely by virtue of receiving Securities under the Transaction Documents or under any other written agreement between the Company and the Purchasers&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no such Purchaser owns any equity in the Company prior to its purchase of the Securities hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information regarding the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall use the net proceeds from the sale of the Shares hereunder to pay the Upfront Payment (as such term is defined in the Janssen License Agreement) and for working capital and general corporate purposes. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Indemnification of Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (and in addition to the indemnification provisions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section&#160;15 of the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Securities Act and Section&#160;20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Purchaser Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a)&#160;any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&#160;any action instituted against a Purchaser in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser may have with any such stockholder or any violations by the Purchaser of state or federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). Promptly after receipt by any Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity may be sought pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless&#58; (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel&#59; (ii) the Company shall have failed promptly to assume the defense of such proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding&#59; or (iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Principal Trading Market Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the time and manner required by the Principal Trading Market, the Company shall prepare and file with such Principal Trading Market an additional shares listing application covering all of the Conversion Shares and shall use its commercially reasonable efforts to take all steps necessary to cause all of the Conversion Shares to be approved for listing on the Principal Trading Market as promptly as possible thereafter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Form&#160;D&#59; Blue Sky</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company agrees to timely file a Form&#160;D with respect to the Securities as required under Regulation&#160;D and to provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, if applicable, shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to the Purchasers under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States (or to obtain an exemption from such qualification) and shall provide evidence of such actions promptly upon the written request of any Purchaser.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Delivery of Shares After Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall deliver, or cause to be delivered, evidence of book entry registration representing the respective Shares purchased by each Purchaser to such Purchaser within two (2) Trading Days of the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Short Sales and Confidentiality After the Date Hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in any transactions in the Company&#8217;s securities (including, without limitation, any Short Sales involving the Company&#8217;s securities) during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced as required by and described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (ii) this Agreement is terminated in full pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Transaction Documents. Notwithstanding the foregoing, no Purchaser makes any representation, warranty or covenant hereby that it will not engage in Short Sales in the securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each Purchaser agrees, severally and not jointly with any Purchasers, that they will not enter into any Net Short Sales (as hereinafter defined) from the period commencing on the Closing Date and ending on the earliest of (x) the Effective Date of the initial Registration Statement, (y) the twenty-four (24) month anniversary of the Closing Date or (z) the date that such Purchaser no longer holds any Securities. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Net Short Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; by any Purchaser shall mean a sale of Common Stock by such Purchaser that is marked as a short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by such Purchaser. For purposes of determining whether there is an equivalent offsetting position in Common Stock held by the Purchaser, Conversion Shares that have not yet been issued pursuant to the conversion of the Shares shall be deemed to be held long by the Purchaser, and the amount of shares of Common Stock held in a long position shall be all unconverted Conversion Shares (ignoring any exercise limitations included therein) issuable to such Purchaser on such date, plus any shares of Common Stock or Common Stock Equivalents otherwise then held by such Purchaser. Notwithstanding the foregoing, in the event that a Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Moreover, notwithstanding the foregoing, in the event that a Purchaser has sold Securities pursuant to Rule 144 prior to the Effective Date of the Registration Statement and the Company has failed to deliver via DTC Securities that are free of all restrictive and other legends prior to the settlement date for such sale (assuming that such electronic certificates meet the requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the removal of legends), the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not prohibit the Purchaser from entering into Net Short Sales for the purpose of delivering shares of Common Stock in settlement of such sale. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Subsequent Equity Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except for an Exempt Issuance, from the date hereof until ninety (90) days after the Effective Date, neither the Company nor any Subsidiary shall issue shares of Common Stock or Common Stock Equivalents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the ninety (90) day period set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be extended for the number of Trading Days during such period in which (i) trading in the Common Stock is suspended by any Trading Market, or (ii) following the Effective Date, the Registration Statement is not effective or the prospectus included in the Registration Statement may not be used by the Purchasers for the resale of the Conversion Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Registration Procedures and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">as soon as practicable following receipt of the Stockholder Approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Filing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) but, in any event, not later than twenty (20) days thereafter, file a registration statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with the Commission to register the offer and sale to the public of all of the Registrable Shares on Form S-3 under the Securities Act (providing for shelf registration of such Registrable Shares under Commission Rule 415). It shall be a condition precedent to the obligations of the Company to file the Registration Statement with respect to the Registrable Shares of a particular Purchaser that such Purchaser furnish to the Company (x) a customary completed selling stockholder questionnaire and (y) such further information regarding such Purchaser, the Registrable Shares held by such Purchaser and the intended method of disposition of the Registrable Shares held by such Purchaser as shall be reasonably required to effect the effectiveness of the registration of such Registrable Shares. In the event that Form S-3 is not available for the registration of the Registrable Shares, the Company shall register the offer and sale to the public of the Registrable Shares on such other Registration Statement form as is available to the Company and undertake to register the Registrable Shares on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Shares has been declared effective by the Commission&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">use its commercially reasonable efforts to cause such Registration Statement required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be declared effective within fifteen (15) days following the Filing Date (or, in the event the Staff reviews and has written comments to the Registration Statement, within forty-five (45) days following the Filing Date) (the earlier of the foregoing or the applicable date set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Effectiveness Deadline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), such efforts to include, without limiting the generality of the foregoing, preparing and filing with the Commission any financial statements or other information that is required to be filed prior to the effectiveness of such Registration Statement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.53pt">prepare and file with the Commission such amendments and supplements to any Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective and free from any material misstatement or omission to state a material fact therein until the earlier of&#58; (A) the date as of which all Registrable Shares have been sold pursuant to the Registration Statement and (B) that date as of which no Registration Shares remain outstanding, subject to the Company&#8217;s right to suspend pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">furnish to the Purchasers such number of copies of prospectuses in conformity with the requirements of the Securities Act and such other documents as the Purchasers may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Registrable Shares by the Purchasers&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">file such documents as may be required of the Company for normal securities law clearance for the offer and sale of the Registrable Shares in such states of the United States as may be reasonably requested by the Purchasers and use its commercially reasonable efforts to maintain such blue sky qualifications during the period the Company is required to maintain effectiveness of the Registration Statement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company shall not be required in connection with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to qualify as a foreign corporation or execute a general consent to service of process in any jurisdiction in which it is not now so qualified or has not so consented or subject the Company to any material tax in any such jurisdiction where it is not then so subject&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">upon notification by the Commission that the Registration Statement will not be reviewed or is not subject to further review by the Commission, within three (3) Trading Days </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">following the date of such notification, request acceleration of such Registration Statement (with the requested effectiveness date to be not more than two (2) Trading Days later)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.08pt">upon notification by the Commission that that the Registration Statement has been declared effective (the date of such notification, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by the Commission, file the final prospectus under Rule 424 within the applicable time period prescribed by Rule 424&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.03pt">advise the Purchasers promptly, and in any event within twenty-four (24) hours of (A) the effectiveness of the Registration Statement or any post-effective amendments thereto, (B) any request by the Commission for amendments to the Registration Statement or amendments to the prospectus or for additional information relating thereto, (C) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement under the Securities Act or of the suspension by any state securities commission of the qualification of the Registrable Shares for offering or sale in any jurisdiction, or the initiation of any proceeding for any of the preceding purposes and (D) the existence of any fact and the happening of any event that makes any statement of a material fact made in the Registration Statement, the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires the making of any additions to or changes in the Registration Statement or the prospectus in order to make the statements therein not misleading&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">cause all Registrable Shares to be listed on each securities exchange on which equity securities by the Company are then listed, if any&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">bear all expenses in connection with the procedures in paragraphs (i) through (ix) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the registration of the Registrable Shares on such Registration Statement and the satisfaction of the blue sky laws of such states.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Liquidated Damages.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If (i) the Registration Statement covering the Registrable Shares is not filed with the Commission on or prior to the Filing Date or (ii) the Registration Statement covering the Registrable Shares is not declared effective by the SEC by the Effectiveness Deadline (each such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Registration Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then, in addition to any other rights the Investor may have hereunder or under applicable law, the Company will make pro rata payments to the Purchasers, as liquidated damages and not as a penalty (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Liquidated Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in an amount equal to one percent (1.0%) of the aggregate amount invested by such Purchaser for the Registrable Shares then held by such Purchaser for the initial day of a Registration Failure and, thereafter in an amount equal to one percent (1.0%) for each thirty (30)-day period until such Registration Failure is cured. The Liquidated Damages shall be paid monthly within ten (10) business days of the date of such Registration Failure and the end of each subsequent thirty (30)-day period (or portion thereof with respect to a final period, if any) thereafter until the Registration Failure is cured. Such payments shall be made in cash to the Purchaser. Interest shall accrue at the rate of one percent (1%) per month on any such liquidated damages payments that shall not be paid by the applicable payment date until such amount is paid in full.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Rule 415 Cutback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If at any time the Staff takes the position that the offering of some or all of the Registrable Shares in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act or requires any Purchaser to be named as an &#8220;underwriter,&#8221; the Company shall use its commercially reasonable efforts to persuade the Commission that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#8220;by or on behalf of the issuer&#8221; as defined in Rule 415 and that none of the Purchasers is an &#8220;underwriter.&#8221; The Purchasers shall have the right to review and oversee any registration or matters pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, including any participation in meetings or discussions with the Commission regarding the Commission&#8217;s position and to comment on any written submission made to the Commission with respect </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereto. In the event that, despite the Company&#8217;s commercially reasonable efforts and compliance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Staff refuses to alter its position, the Company shall (A) remove from the Registration Statement such portion of the Registrable Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cut Back Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and&#47;or (B) agree to such restrictions and limitations on the registration of the Registrable Shares as the Commission may require to assure the Company&#8217;s compliance with the requirements of Rule 415 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">SEC Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company shall not agree to name any Purchaser as an &#8220;underwriter&#8221; in such Registration Statement without the prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be allocated among the Purchasers on a pro rata basis and shall be applied first to any of the Registrable Shares of such Purchaser as such Purchaser shall designate, unless the SEC Restrictions otherwise require or provide or the Purchasers otherwise agree. No damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Restriction Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall again be applicable to such Cut Back Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (x) the filing deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Trading Days after such Restriction Termination Date, and (y) the Effectiveness Deadline with respect to such Cut Back Shares shall be the 90th day immediately after the Restriction Termination Date or the 120th day if the Staff reviews such Registration Statement (but in any event no later than three (3) Trading Days from the Staff indicating it has no further comments on such Registration Statement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Requests for Underwritten Shelf Takedowns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 4.15(j), at any time and from time to time when the Registration Statement is effective, each Purchaser may request to sell all or any portion of their respective Registrable Shares in an underwritten offering that is registered pursuant to the Registration Statement, including a Block Trade (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Shelf Takedown</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and as soon as practicable the Company shall amend or supplement the Registration Statement as necessary for such purpose&#59; provided in each case that (1) the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include Registrable Shares proposed to be sold in such Underwritten Shelf Takedown with a total offering price reasonably expected to exceed, in the aggregate, $30.0 million (based on the closing price on the Trading Day immediately preceding the date of the demand) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Minimum Takedown Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Purchasers may make only one demand of Underwritten Shelf Takedown in any 6-month period. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company&#160;at least two (2) Business Days prior to the public announcement of such&#160;Underwritten&#160;Shelf&#160;Takedown, which notice shall specify the approximate number of Registrable Shares proposed to be sold in the Underwritten Shelf Takedown. Promptly (but in any event within two (2) Business Days) after receipt of a request for Underwritten Shelf Takedown, the Company shall give written notice of the Underwritten Shelf Takedown to all other Purchasers. Such notice shall offer each other Purchaser the opportunity to include in any Underwritten Shelf Takedown such number of Registrable Shares as each such Purchaser may request in writing within five (5) Business Days after the date that the notice has been delivered to such Purchaser. The Company shall have the right to select the underwriters and their respective roles for such offering, subject to the initial demanding Purchaser&#8217;s prior approval (which shall not be unreasonably withheld, conditioned or delayed) if the Company is offering any shares in such Underwritten Shelf Takedown. If the Company is not offering any shares in such Underwritten Shelf Takedown, then the underwriters (and their respective roles) in such Underwritten Shelf Takedown will be determined by the initial demanding Purchaser, subject to the Company&#8217;s prior approval, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Reduction of Underwritten Shelf Takedown.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If, in connection with an Underwritten Shelf Takedown that is effectuated for the account of stockholders of the Company, including pursuant to </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.15(d), in which Registrable Shares are included, the managing underwriters of such Underwritten Shelf Takedown advise the Company in writing that, in their opinion and in consultation with the Company, the number of Registrable Shares requested to be included in such Underwritten Shelf Takedown exceeds the number that can be sold in such Underwritten Shelf Takedown and&#47;or that the number of Registrable Shares proposed to be included in any such Underwritten Shelf Takedown would adversely affect the price per share of the equity securities to be sold in such Underwritten Shelf Takedown (such maximum number of securities or Registrable Shares, as applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Maximum Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the number of Registrable Shares to be included in such Underwritten Shelf Takedown shall be allocated pro rata, based on the amount of such Registrable Shares initially requested to be included by the applicable Purchasers pursuant to either Section 4.15(c) or as such Purchasers may otherwise agree, that can be sold without exceeding the Maximum Threshold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Withdrawal of Underwritten Shelf Takedown</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Prior to the filing of the applicable &#8220;red herring&#8221; prospectus or prospectus supplement used for marketing such Underwritten Shelf Takedown, each Purchaser shall have the right to withdraw from such Underwritten Shelf Takedown for any or no reason whatsoever upon written notification (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Withdrawal Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Company and the underwriter or underwriters (if any) of their intention to withdraw from such Underwritten Shelf Takedown. Any Purchasers may elect to have the Company continue an Underwritten Shelf Takedown if the Minimum Takedown Threshold would still be satisfied by the Registrable Shares proposed to be sold in the Underwritten Shelf Takedown by the Purchasers. If withdrawn, a demand for an Underwritten Shelf Takedown shall constitute a demand for an Underwritten Shelf Takedown for purposes of Section 4.15(c), unless the demanding Purchasers reimburse the Company for all expenses with respect to such Underwritten Shelf Takedown&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if any Purchaser elects to continue an Underwritten Shelf Takedown pursuant to the proviso in the immediately preceding sentence, such Underwritten Shelf Takedown shall continue to count as an Underwritten Shelf Takedown for purposes of Section 4.15(c). Following the receipt of any Withdrawal Notice, the Company shall promptly forward such Withdrawal Notice to any other Purchasers that had elected to participate in such Underwritten Shelf Takedown. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the expenses incurred in connection with an Underwritten Shelf Takedown prior to its withdrawal under this Section 4.15(e), other than if the demanding Purchasers elect to pay such expenses pursuant to the second sentence of this Section 4.15(e).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Other Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, but subject to Section 4.15(j), at any time and from time to time when the Registration Statement is on file and effective with the Commission, if any Purchaser wishes to engage in an &#8220;at the market&#8221; or similar registered offering through a broker, sales agent or distribution agent, whether as agent or principal (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), such Purchaser shall notify the Company of the Other Offering at least five (5) Business Days prior to the day such offering is to commence and the Company shall as expeditiously as possible use its commercially reasonable efforts to facilitate such Other Offering&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Purchasers wishing to engage in the Other Offering shall use commercially reasonable efforts to work with the Company and any placement agents or sales agents prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation related to the Other Offering&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that in the case of such Other Offering, only such Purchaser initiating such Other Offering shall have a right to notice of and to participate in such offering.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Registration and Offering Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> All Sale Expenses (as defined below) incurred in connection with Section 4.15(d) and Section 4.15(g) shall be borne by the Company. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sale Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) the fees and disbursements of counsel of the Company and independent public accountants for the Company incurred in connection with the Registration Statement, Underwritten Shelf Takedown, Block Trade or Other Offering, including the expenses of any special audits or &#8220;comfort&#8221; letters required by any such Underwritten Shelf Takedown, Block Trade or Other Offering , (b) all registration, filing and stock </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">exchange fees, all fees and expenses of complying with securities or &#8220;blue sky&#8221; laws (including any legal investment memoranda related thereto), all fees and expenses of custodians, transfer agents and registrars, all printing and producing expenses, (c) the reasonable fees and disbursements of one legal counsel for all Purchasers participating in any Underwritten Shelf Takedown, Block Trade or Other Offering&#59; provided, however, that &#8220;Sale Expenses&#8221; shall not include any out-of-pocket expenses of any Purchaser, transfer taxes, underwriting or brokerage commissions or discounts associated with effecting any sales of Registrable Securities that may be offered, which expenses shall be borne by such Purchaser. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">The Company agrees to indemnify and hold harmless each Purchaser Party, to the fullest extent permitted by applicable law, from and against any losses, claims, damages or liabilities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), joint or several, to which they may become subject (under the Securities Act or otherwise) insofar as such Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement by the Company or any untrue or alleged untrue statement of a material fact contained in the Registration Statement or any omission or alleged omission to state a material fact required to be stated in the prospectus contained therein or necessary to make the statements in the prospectus contained therein, in light of the circumstances under which they were made, not misleading or arise out of any failure by the Company to fulfill any undertaking included in the Registration Statement and the Company will, as incurred, reimburse the Purchaser Parties for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company shall not be liable in any such case to the extent that such Loss arises out of, or is based upon&#58; (A) an untrue statement or omission made in such Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Purchaser specifically for inclusion in the Registration Statement or (B) any breach of this Agreement by such Purchaser&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company shall not be liable to any Purchaser Party (or any partner, member, officer, director or controlling Person of the Purchasers) to the extent that any such Loss is caused by an untrue statement or omission made in any preliminary prospectus if either (1) (a) such Purchaser failed to send or deliver a copy of the final prospectus with or prior to, or such Purchaser failed to confirm that a final prospectus was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by such Purchaser to the Person asserting the claim from which such Loss resulted and (b) the final prospectus corrected such untrue statement or omission, (2) (x) such untrue statement or omission is corrected in an amendment or supplement to the prospectus and (y) having previously been furnished by or on behalf of the Company with copies of the prospectus as so amended or supplemented or notified by the Company that such amended or supplemented prospectus has been filed with the Commission, in accordance with Rule 172 of the Securities Act, such Purchaser thereafter fails to deliver such prospectus as so amended or supplemented, with or prior to or a Purchaser fails to confirm that the prospectus as so amended or supplemented was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by such Purchaser to the Person asserting the claim from which such Loss resulted or (3) such Purchaser sold Registrable Shares in violation of such Purchasers&#8217; covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">Each Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company and its officers, directors, employees, affiliates, agents and representatives and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), from and against any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any untrue statement of a material fact contained in the Registration Statement (or any omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">circumstances under which they were made, not misleading in each case, on the effective date thereof), if, and only to the extent, such untrue statement or omission was made in reliance upon and in conformity with written information furnished by or on behalf of such Purchaser specifically for inclusion in the Registration Statement, and each Purchaser, severally and not jointly, will reimburse each Company Party for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that in no event shall any indemnity under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Purchaser in connection with any claim relating to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the amount of any damages such Purchaser has otherwise been required to pay by reason of such untrue statement or omission) received by such Purchaser upon its sale of the Registrable Shares included in the Registration Statement giving rise to such indemnification obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.53pt">Promptly after receipt by any indemnified Person of a notice of a claim or the beginning of any action in respect of which indemnity is to be sought against an indemnifying Person pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such indemnified Person shall notify the indemnifying Person in writing of such claim or of the commencement of such action, and, subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified Person and such indemnifying Person shall have been notified thereof, such indemnifying Person shall be entitled to participate therein, and, to the extent that it shall wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified Person. After notice from the indemnifying Person to such indemnified Person of its election to assume the defense thereof, such indemnifying Person shall not be liable to such indemnified Person for any legal expenses subsequently incurred by such indemnified Person in connection with the defense thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if there exists or shall exist a conflict of interest that would make it inappropriate in the reasonable judgment of the indemnified Person for the same counsel to represent both the indemnified Person and such indemnifying Person or any affiliate or associate thereof, the indemnified Person shall be entitled to retain its own counsel at the expense of such indemnifying Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no indemnifying Person shall be responsible for the fees and expense of more than one separate counsel for all indemnified parties. The indemnifying party shall not settle an action without the consent of the indemnified party, which consent shall not be unreasonably withheld.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">If after proper notice of a claim or the commencement of any action against the indemnified party, the indemnifying party does not choose to participate, then the indemnified party shall assume the defense thereof and upon written notice by the indemnified party requesting advance payment of a stated amount for its reasonable defense costs and expenses, the indemnifying party shall advance payment for such reasonable defense costs and expenses (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Advance Indemnification Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the indemnified party. In the event that the indemnified party&#8217;s actual defense costs and expenses exceed the amount of the Advance Indemnification Payment, then upon written request by the indemnified party, the indemnifying party shall reimburse the indemnified party for such difference&#59; in the event that the Advance Indemnification Payment exceeds the indemnified party&#8217;s actual costs and expenses, the indemnified party shall promptly remit payment of such difference to the indemnifying party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">If the indemnification provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other, as well as any other relevant equitable considerations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that in no event shall any contribution by a Purchaser hereunder be greater in amount than the dollar amount of the proceeds received by such Purchaser upon the sale of such Registrable Shares. No person guilty of fraudulent misrepresentation within </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Prospectus Suspension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Purchaser acknowledges that there may be times when the Company must suspend the use of the prospectus forming a part of a Registration Statement until such time as an amendment to such Registration Statement has been filed by the Company and declared effective by the Commission, or until such time as the Company has filed an appropriate report with the Commission pursuant to the Exchange Act. Each Purchaser hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at the time at which the Company gives the Purchasers notice of the suspension of the use of said prospectus and ending at the time the Company gives the Purchasers notice that the Purchasers may thereafter effect sales pursuant to said prospectus&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that such suspension periods shall in no event exceed thirty (30) consecutive calendar days or a total of sixty (60) calendar days (which need not be consecutive calendar days) in any 12-month period and that, in the good faith judgment of the Company&#8217;s Board of Directors, the Company would, in the absence of such delay or suspension hereunder, be required under state or federal securities laws to disclose any corporate development, a potentially significant transaction or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto, in either case the disclosure of which would reasonably be expected to have a Material Adverse Effect upon the Company or its stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Termination of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of the Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof shall cease and terminate, with respect to any Registrable Shares, upon the earlier to occur of (i) such time such Registrable Shares have been resold, or (ii) such time as such Shares no longer remain Registrable Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With a view to making available the benefits of certain rules and regulations of the Commission that may at any time permit the sale of the Registrable Shares to the public without registration or pursuant to a registration statement on Form S-3, the Company agrees to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">make and keep public information available, as those terms are understood and defined in Rule 144&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">so long as a Purchaser owns Registrable Shares, to furnish to such Purchaser upon request (A) a written statement by the Company as to whether it is in compliance with the reporting requirements of Rule 144 and the Exchange Act, or whether it is qualified as a registrant whose securities may be resold pursuant to Form S-3 and (B) such other information as may be reasonably requested to permit the Purchaser to sell such securities pursuant to Rule 144.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall, as soon as practicable following the Closing, but not more than thirty (30) days thereafter, file a preliminary proxy statement for a vote of its stockholders to approve (i) the issuance of all Conversion Shares upon conversion of the Shares in compliance with Nasdaq Listing Rule 5635(b) and&#47;or (d),  (ii) an amendment to the Company&#8217;s certificate of incorporation to increase its authorized number of shares of Common Stock to enable the issuance or reservation for issuance, as applicable, of all of the Conversion Shares (without regard to any limitations on conversion set forth in the Certificate of Designation) in compliance with the rules and regulations of Nasdaq (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Transaction Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (iii) the Pool Increase (as defined below) and (iv) other customary annual stockholder meeting matters (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Additional Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and together with the Transaction Proposals, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company shall, as soon as practicable following notification from the Staff that it has completed its review of the preliminary proxy statement or that it will not review the preliminary proxy statement, file and mail a definitive proxy statement for the vote of its stockholders to approve the Proposals. The Company covenants and agrees that its Board of Directors shall unanimously recommend that the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proposals be approved by the Company&#8217;s stockholders at all meetings in which such Proposals are considered and promptly file, if applicable, the necessary amendments to the Company&#8217;s certificate of incorporation after the Proposals are approved. If the Company&#8217;s stockholders do not approve the Transaction Proposals at the first meeting in which they are voted on by the stockholders, the Company covenants and agrees that it will submit the Transaction Proposals for approval of the Company&#8217;s stockholders at least annually until such approval is obtained.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Option Pool Increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Board of Directors shall approve and recommend and the Company shall submit to its stockholders to approve an increase to the reserved shares under the Company&#8217;s 2015 Equity Incentive Plan at an amount no greater than 46,690,100 shares and the Company shall submit such increase to its stockholders for approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Pool Increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any conversion from Series A Preferred Stock into Common Stock, the Company and each Purchaser (i) shall use their respective commercially reasonable efforts to promptly file or cause to be filed, (x) within ten (10) Business Days from the date that either the Company or any Purchaser provides any notice of conversion required pursuant to Section 6 of the Certificate of Designation (for which within five (5) Business Days the Purchaser determines that a filing under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">HSR Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is necessary or appropriate, and so notifies the Company), all required filings under the HSR Act and (y) as promptly as reasonably practicable, all required filings under other applicable antitrust laws that the Company or any Purchaser reasonably determines in good faith to be necessary or appropriate to effect the transactions contemplated by this Agreement including, but not limited to, the conversion of Series A Preferred Stock into Common Stock, (ii) shall consult and cooperate with each other in the preparation of such filings, and (iii) shall promptly inform the other parties of any material communication received by such party from any Governmental Entity regarding the transactions contemplated by this Agreement and shall enable the other party to participate in any communications and meetings with any Governmental Entity regarding the transactions contemplated by this Agreement unless prohibited by the Governmental Entity. Each of the Company and any Purchaser that files such notice pursuant to the HSR Act or any other applicable antitrust law in accordance with the preceding sentence acknowledges that no conversion of Series A Preferred Stock into Common Stock will be consummated until any waiting period prescribed under the HSR Act or any other applicable antitrust law has elapsed.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE V.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDITIONS PRECEDENT TO CLOSING</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Conditions Precedent to the Obligations of the Purchasers to Purchase Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligation of each Purchaser to acquire Shares at the Closing is subject to the fulfillment to such Purchaser&#8217;s satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by such Purchaser (as to itself only)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The representations and warranties made by the Company in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof shall be true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and as of such date, except for such representations and warranties that speak as of a specific date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">No Injunction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Other than the Stockholder Approval, the Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary for consummation of the purchase and sale of the Securities (including all Required Approvals), all of which shall be and remain so long as necessary in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Adverse Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160; The Company or its counsel shall have submitted a Listing of Additional Shares notification form with the Nasdaq Stock Market LLC covering the Conversion Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">No Suspensions of Trading in Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal Trading Market have been threatened, as of the Closing Date, either (i) in writing by the Commission or the Principal Trading Market or (ii) by falling below the minimum listing maintenance requirements of the Principal Trading Market.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Company Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall have delivered the Company Deliverables in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 5.1(a),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">Due Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall have provided the Purchasers with all documents and materials reasonably requested by the Purchasers in connection with their due diligence review.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall not have been terminated as to such Purchaser in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall have consummated all transactions contemplated by  the Janssen License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt;text-decoration:underline">Board Appointments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Timothy Franson, M.D. and David Gollaher, Ph.D., shall have tendered their resignations from the board of directors of the Company and the Company shall have appointed Laura Tadvalkar, Ph.D. as a Class II director, James Merson, Ph.D. as a Class III director and Ryan Spencer as a Class I director effective as of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Conditions Precedent to the Obligations of the Company to Sell Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company&#8217;s obligation to sell and issue the Shares at the Closing to the Purchasers is subject to the fulfillment to the Company&#8217;s satisfaction on or prior to the Closing Date of the following conditions, any of which may be waived by the Company&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The representations and warranties made by the Purchasers in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof shall be true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made, and as of the Closing Date as though made on and as of such date, except for representations and warranties that speak as of a specific date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">No Injunction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Purchasers Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;This Agreement shall not have been terminated as to such Purchaser in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> herein.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.51pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall pay all Transfer Agent fees, stamp taxes and other Taxes and duties levied in connection with the sale and issuance of the Securities to the Purchasers and all expenses in connection with obtaining Stockholder Approval and the registration of the Conversion Shares. The Company shall reimburse each of RA Capital and BCLS for reasonable costs and expenses incurred in connection with the transactions contemplated by the Transaction Documents, including without limitation the reasonable and documented legal fees and expenses of each.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> prior to 5&#58;00 P.M., New York City time, on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on a day that is not a Trading Day or later than 5&#58;00 P.M., New York City time, on any Trading Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to the Company&#58;&#160;&#160;&#160;&#160;Cidara Therapeutics, Inc.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6310 Nancy Ridge Drive, Suite 101</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, California 92121</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; legal&#64;cidara.com</font></div><div style="padding-left:108pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cooley LLP </font></div><div style="padding-left:121.7pt;text-indent:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10265 Science Center Drive</font></div><div style="padding-left:121.7pt;text-indent:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, California 92121 </font></div><div style="padding-left:121.7pt;text-indent:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Charles J. Bair, Esq.</font></div><div style="padding-left:121.7pt;text-indent:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CBair&#64;cooley.com</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to a Purchaser&#58;&#160;&#160;&#160;&#160;To the address set forth under such Purchaser&#8217;s name on the signature page &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;hereof</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:13.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;Goodwin Procter LLP</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The New York Times Building</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">620 Eighth Avenue</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Dan Lang</font></div><div style="padding-left:121.7pt;text-indent:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DLang&#64;goodwinlaw.com&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or such other address as may be designated in writing hereafter, in the same manner, by such Person.</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Amendments&#59; Waivers&#59; No Additional Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers of at least sixty-five percent (65%) in interest of the Securities, if prior to the Closing Date, to be purchased by the Purchasers hereunder, or, if after the Closing Date, still held by Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. Notwithstanding the foregoing, this Agreement may not be amended, modified, supplemented or terminated and the observance of any term hereof may not be waived with respect to any Purchaser without the written consent of such Purchaser, unless such amendment, modification, supplement, termination, or waiver applies to all Purchasers in the same fashion.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also offered to all Purchasers who then hold Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the prior written consent of each </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchaser. Any Purchaser may assign its rights hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred Securities, by the terms and conditions of this Agreement that apply to the &#8220;Purchasers.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except  each Purchaser Party is an intended third-party beneficiary of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the courts of the State of New York or into the Federal Court located in New York, New York. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the courts of the State of New York or into the Federal Court located in New York, New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of the aforesaid courts, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to applicable statute of limitations, the representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery of the Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Rescission and Withdrawal Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Replacement of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any certificate or instrument evidencing any Securities, if applicable, is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Payment Set Aside</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Adjustments in Share Numbers and Prices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Independent Nature of Purchasers&#8217; Obligations and Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchaser and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any Purchaser. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to the Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated on or prior to 5&#58;00 P.M., New York City time, on the Outside Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the right to terminate this Agreement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction Documents as a result therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></div></div></div><div id="i9a0407bc8d95489ba95e50971d54402a_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-bottom:24pt;padding-left:211.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</font></div><div style="margin-bottom:24pt;padding-left:234pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jeffrey Stein, Ph.D.                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<br>Name&#58;  Jeffrey Stein, Ph.D.&#160;&#160;&#160;&#160;<br>Title&#58;   President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt;padding-left:234pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;<br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RA CAPITAL HEALTHCARE FUND, L.P.</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; RA Capital Healthcare Fund GP, LLC</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58; General Partner</font></div><div style="margin-top:10.05pt;padding-left:198pt;padding-right:74.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Peter Kolchinsky&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Name&#58; Peter Kolchinsky</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Manager</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $100,000,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 100,000</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BCLS FUND III INVESTMENTS, LP</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BCLS Fund III Investments GP, LLC,</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">its general partner</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; Bain Capital Life Sciences Fund III, L.P.,</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">its member</font></div><div style="padding-left:198pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; Bain Capital Life Sciences III General Partner, LLC,</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">its general partner</font></div><div style="padding-left:198pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; Bain Capital Life Sciences Investors, LLC,</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">its manager</font></div><div style="padding-left:198pt"><font><br></font></div><div style="margin-top:10.05pt;padding-left:198pt;padding-right:74.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Andrew Hack&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Name&#58; Andrew Hack</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Partner</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $100,000,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 100,000</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">CANAAN XII L.P.</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; Canaan Partners XII LLC, its General Partner</font></div><div style="padding-left:198pt"><font><br></font></div><div style="margin-top:10.05pt;padding-left:198pt;padding-right:74.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Tim Shannon&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Name&#58; Dr. Tim Shannon</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Member&#47;Manager</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $20,000,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 20,000</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">BIOTECHNOLOGY VALUE FUND, L.P.</font></div><div style="margin-top:1.05pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF I GP LLC, its general partner</font></div><div style="margin-top:1.05pt;padding-left:198pt"><font><br></font></div><div style="margin-top:10.05pt;padding-left:216pt;padding-right:74.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Mark N. Lampert&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Mark N. Lampert</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $10,594,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 10,594</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">BIOTECHNOLOGY VALUE FUND II, L.P.</font></div><div style="margin-top:1.05pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF II GP LLC, its general partner</font></div><div style="margin-top:1.05pt;padding-left:198pt"><font><br></font></div><div style="margin-top:10.05pt;padding-left:216pt;padding-right:74.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Mark N. Lampert&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Mark N. Lampert</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $8,416,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 8,416</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">BIOTECHNOLOGY VALUE TRADING FUND OS LP</font></div><div style="margin-top:1.05pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF Partners OS Ltd., its general partner</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF Partners L.P., its sole member</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF Inc., its general partner</font></div><div style="padding-left:198pt"><font><br></font></div><div style="margin-top:10.05pt;padding-left:216pt;padding-right:74.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Mark N. Lampert&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Mark N. Lampert</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $692,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 692</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></div><div style="margin-top:10pt;padding-left:235.55pt"><font><br></font></div><div style="margin-top:10pt;padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NAME OF PURCHASER&#58;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">MSI BVF SPV, LLC</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF Partners L.P., its attorney-in-fact</font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">By&#58; BVF Inc., its General Partner</font></div><div><font><br></font></div><div style="margin-top:10.05pt;padding-left:216pt;padding-right:74.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%;text-decoration:underline">&#47;s&#47; Mark N. Lampert&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%"> Mark N. Lampert</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President</font></div><div style="margin-top:9.2pt"><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aggregate Purchase Price (Subscription Amount)&#58; $298,000</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Number of Shares to be Acquired&#58; 298</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tax ID No.&#58;</font></div><div><font><br></font></div><div style="padding-left:198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notice&#58;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><div id="i9a0407bc8d95489ba95e50971d54402a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBITS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A&#58;&#160;&#160;&#160;&#160;Certificate of Designation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B-1&#58; &#160;&#160;&#160;&#160;Accredited Investor Questionnaire</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B-2&#58;&#160;&#160;&#160;&#160;Book Entry Questionnaire</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C&#58; &#160;&#160;&#160;&#160;Form of Irrevocable Transfer Agent Instructions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">D&#58;&#160;&#160;&#160;&#160;Form of Secretary&#8217;s Certificate</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E&#58;&#160;&#160;&#160;&#160;Form of Officer&#8217;s Certificate</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">F&#58;&#160;&#160;&#160;&#160;Wire Instructions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G&#58; &#160;&#160;&#160;&#160;Form of Support Agreement</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CERTIFICATE OF DESIGNATION</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:71.25pt;text-align:justify;text-indent:-37.05pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT B-1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACCREDITED INVESTOR QUESTIONNAIRE</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT B-2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BOOK ENTRY QUESTIONNAIRE</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FORM OF IRREVOCABLE TRANSFER AGENT INSTRUCTIONS</font></div><div><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FORM OF SECRETARY&#8217;S CERTIFICATE</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:270pt;text-align:right;text-indent:-17.6pt"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FORM OF OFFICER&#8217;S CERTIFICATE</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT F</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WIRE INSTRUCTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT G</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FORM OF SUPPORT AGREEMENT</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>exhibit1022024-04x24.htm
<DESCRIPTION>FORM OF SUPPORT AGREEMENT
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i75b6346b730948d699f3eeaec56ef0a7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUPPORT AGREEMENT </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUPPORT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), dated as of April 23, 2024, is made by and among Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the other persons and entities set forth on the signature pages hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company and the Stockholders shall be referred to herein from time to time collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Company and certain investors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) entered into that certain Securities Purchase Agreement, dated as of the date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, as of the date of this Agreement, each of the Stockholders own that number of shares of common stock, par value $0.0001 per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) set forth opposite its name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Purchase Agreement contemplates that the Parties will enter into this Agreement concurrently with the entry into the Purchase Agreement by the parties thereto, pursuant to which, among other things, the Stockholders will vote in favor of approval of the Proposals (as defined in the Purchase Agreement). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.25pt">Agreement to Vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">For so long as this Agreement is in effect, each Stockholders hereby agrees to appear (in person or by proxy) and vote (in person or by proxy) at any meeting of the stockholders of the Company (including any adjournment or postponement thereof), and in any action by written resolution of the stockholders of the Company (such meeting or written resolution, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), all of such Stockholders&#8217;s Voting Securities that such Stockholder holds of record or beneficially, as of the date of this Agreement, or of which such Stockholder acquires record or beneficial ownership after the date hereof and before the record date of the Meeting (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subject Equity Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in favor of the Transaction Proposals and the Additional Proposals, and against any proposal that conflicts or materially impedes or interferes with the approval of any of the Transaction Proposals or Additional Proposals or that would adversely affect or delay the consummation of the transactions contemplated by the Purchase Agreement. Each Stockholder shall validly execute and deliver to the Company, on (or effective as of) the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Business Day following the date that the Proxy Statement related to the Proposals is disseminated by the Company to the Company&#8217;s stockholders, a properly completed voting proxy in the form distributed by or on behalf of the Company in favor of the Proposals. In the event of any equity dividend or distribution, or any change in the equity interests of the Company by reason of any equity dividend or distribution, equity split, recapitalization, combination, conversion, exchange of equity interests or the like prior to the Closing, the term &#8220;Subject Equity Securities&#8221; shall be deemed to refer to and include the Subject Equity Securities as well as all such equity dividends and distributions and any securities into which or for which any or all of the Subject Equity Securities may be changed or exchanged or which are received in such transaction. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.75pt">Transfer of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">From the date hereof until the earlier of (i) the Automatic Conversion Date (as defined in the Certificate of Designation) or (ii) the valid termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each Stockholder hereby agrees that such Stockholder shall not, directly or indirectly, (i) sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of his, her or its Subject Equity Securities or otherwise agree to do any of the foregoing (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) deposit any of such Stockholder&#8217;s Subject Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of such Stockholder&#8217;s Subject Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii) enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect sale, assignment, transfer (including by operation of law) or other disposition of any of such Stockholder&#8217;s Subject Equity Securities, (iv) engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with one or more events or developments (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of such Stockholder&#8217;s Subject Equity Securities or (v) take any action that would have the effect of preventing or materially delaying the performance of such Stockholder&#8217;s obligations hereunder, except as affirmatively permitted by the Purchase Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the foregoing shall not apply to any Transfer (A) in the case of an individual, by gift to a member of one of the individual&#8217;s immediate family or to a trust, the beneficiary of which is a member of the individual&#8217;s immediate family, an Affiliate of such person or to a charitable organization&#59; (B) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual&#59; (C) in the case of an individual, pursuant to a qualified domestic relations order&#59; and (D) by virtue of such Stockholder&#8217;s organizational documents upon liquidation or dissolution of such Stockholder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that any transferee of any Transfer of the type set forth in clauses (A) through (D) must enter into a written agreement in form and substance reasonably satisfactory to the Company agreeing to be bound by this Agreement prior to the occurrence of such Transfer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">In furtherance of the foregoing, the Company hereby agrees to (i) place a revocable stop order on all Subject Equity Securities subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, including those which may be covered by a registration statement, and (ii) notify the Company&#8217;s transfer agent in writing of such stop order and the restrictions on such Subject Equity Securities under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and direct the Company&#8217;s transfer agent not to process any attempts by the Stockholders to Transfer any Subject Equity Securities except in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For the avoidance of doubt, the obligations of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to be satisfied by the existence of any similar stop order and restrictions currently existing on the Subject Equity Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.75pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall automatically terminate, without any notice or other action by any Party, and be void </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ab initio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> upon the earlier of (a) the Automatic Conversion Date (as defined in the Certificate of Designation)&#59; and (b) three (3) years following the Closing Date (as defined in the Purchase Agreement). Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations under, or with respect to, this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.75pt">Amendments and Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by (i) the Company, (ii) the Purchasers of at least a majority in interest of the Shares, if prior to the Closing Date, to be purchased by the Purchasers under the Purchase Agreement, or, if after the Closing Date, still held by the Purchasers and (iii) at least a majority in interest of the Voting Securities held by the Stockholders (who are not Purchasers). No waiver of any default with respect to any provision, condition or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.75pt">Incorporation by Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Sections 6.3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.5 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.6 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.7 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.8 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.10 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), 6.11 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and 6.14 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of the Purchase Agreement are incorporated herein and shall apply to this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature page follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i75b6346b730948d699f3eeaec56ef0a7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each of the Parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cidara Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                       </font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Jeffrey Stein, Ph.D.</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">STOCKHOLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;_&#93;</font></div><div style="margin-bottom:12pt;padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; __________________</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; </font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;text-indent:-4.5pt"><font><br></font></div></div></div><div id="i75b6346b730948d699f3eeaec56ef0a7_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares of Common Stock Beneficially Owned</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:283.5pt;text-align:justify"><font><br></font></div><div style="padding-left:283.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:265.5pt;text-align:justify"><font><br></font></div><div style="padding-left:265.5pt;text-align:justify"><font><br></font></div><div style="padding-left:265.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cdtx-20240423.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:52c897aa-3db6-4be1-b6e1-6239c81be01d,g:cd5fc6b2-e88f-4fee-81a2-854ad3fb7286-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20240423" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20240423">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20240423_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20240423_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://cidara.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cdtx-20240423_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:52c897aa-3db6-4be1-b6e1-6239c81be01d,g:cd5fc6b2-e88f-4fee-81a2-854ad3fb7286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_a02e36a0-3fd2-403a-ab7f-c872d7b650bf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_686390ad-5e19-4846-82cc-ba9a9c42e8c1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0c1ea75b-713e-472c-8226-fb705cf96528_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b6726c39-7d98-4bd3-b719-676d3022b5fe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2a2fce80-dead-46a5-a02f-4464be6b1273_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c961551f-91a0-44fa-b723-7ba6d6b9d3e5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_105a5c8d-b139-492b-b2b2-2d7c78b3f5da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9e6dc839-c808-4c1f-ae87-09f93f8af8cc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4c19f7b3-d681-466f-a1ca-adb942cecd7d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ea86140b-4686-4bd4-beaf-964fa6f71832_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_843d405a-be89-43f6-8628-6fd9c93df004_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_313369b5-cff4-43e4-9e71-7240b5ea48b3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_8edd7eda-e126-4215-b037-0f669537a601_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0fc8e023-9468-4b8a-a37b-a22cf47aef51_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4120879a-f0dc-4675-a2c9-1a20a0865319_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cc0d92f2-cf77-4c4e-a8b9-81960e0580f1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_47269bea-aa22-4321-ac6d-0c05aef11207_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b35f8c90-ab9f-40bb-8379-7c7cbf858d69_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_285c9fd3-7012-4888-b990-187090bf35f6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5b8936ca-02e9-4884-a888-14f75b03f539_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_26752216-9498-4fd2-a590-e6b19509ae90_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e5265c8-8f47-4702-a630-bbaa3413b5bd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3be61951-c252-4e54-977c-3dc9dd43312e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7c69e305-89d0-4fc1-8a0e-a8e8bbc32d04_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_17342f01-2d15-4f99-b271-e881540b4a63_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cdtx-20240423_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:52c897aa-3db6-4be1-b6e1-6239c81be01d,g:cd5fc6b2-e88f-4fee-81a2-854ad3fb7286-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CoverPage" xlink:type="simple" xlink:href="cdtx-20240423.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e6d5f6b1-c540-4216-a3fc-fb64a2bd62ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_DocumentType_e6d5f6b1-c540-4216-a3fc-fb64a2bd62ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ae52e786-8a60-4e31-bf55-e06400cc45f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_DocumentPeriodEndDate_ae52e786-8a60-4e31-bf55-e06400cc45f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_09c3f28a-a66f-4d2f-a9de-f9a73bd77153" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityRegistrantName_09c3f28a-a66f-4d2f-a9de-f9a73bd77153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_38bdb150-4306-4f8c-be34-a09f1584a646" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_38bdb150-4306-4f8c-be34-a09f1584a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_35596e7e-bc58-4f94-ac80-dd8e900c913d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityFileNumber_35596e7e-bc58-4f94-ac80-dd8e900c913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_160a3743-0864-4a04-afdc-1df6212c90ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityTaxIdentificationNumber_160a3743-0864-4a04-afdc-1df6212c90ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cd472fc1-0e61-428e-8f66-2555ae37df76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityAddressAddressLine1_cd472fc1-0e61-428e-8f66-2555ae37df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1efaf7bd-97ca-4e3f-a32c-6abd3e226fa2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityAddressAddressLine2_1efaf7bd-97ca-4e3f-a32c-6abd3e226fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2650f765-1d3c-455e-aff2-cc24e3811bc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityAddressCityOrTown_2650f765-1d3c-455e-aff2-cc24e3811bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_917d4395-efc8-47c2-a7c6-cfb9a64af8f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityAddressStateOrProvince_917d4395-efc8-47c2-a7c6-cfb9a64af8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cabb2fa3-72cb-47eb-b6c9-991f3bd6ea0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityAddressPostalZipCode_cabb2fa3-72cb-47eb-b6c9-991f3bd6ea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3b94c02c-81fb-4a06-8fe3-6f3a5abd0084" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_CityAreaCode_3b94c02c-81fb-4a06-8fe3-6f3a5abd0084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c8fe3145-968a-41d8-98dc-e9796f6af39f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_LocalPhoneNumber_c8fe3145-968a-41d8-98dc-e9796f6af39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_68d22ee3-6969-4728-a1de-25bdbc766595" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_WrittenCommunications_68d22ee3-6969-4728-a1de-25bdbc766595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_87b1b017-bec0-4649-9bf9-1f90fe6d42b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_SolicitingMaterial_87b1b017-bec0-4649-9bf9-1f90fe6d42b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2661844c-5469-435c-a8c4-e12b541188cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_PreCommencementTenderOffer_2661844c-5469-435c-a8c4-e12b541188cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_37b252ff-9fa5-4112-a16c-05c321c0d279" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_37b252ff-9fa5-4112-a16c-05c321c0d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e21c10b9-d4a5-42c2-a50c-45b97070df47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_Security12bTitle_e21c10b9-d4a5-42c2-a50c-45b97070df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bfb3a419-7e69-43c2-bfb9-a84adb45279b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_TradingSymbol_bfb3a419-7e69-43c2-bfb9-a84adb45279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fb7f6464-1e34-4514-9cf5-cbd912a7feab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_SecurityExchangeName_fb7f6464-1e34-4514-9cf5-cbd912a7feab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a9a22786-0573-4ecc-8826-4359b65338f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityEmergingGrowthCompany_a9a22786-0573-4ecc-8826-4359b65338f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b23fd334-98ad-4c6c-bc3d-4072f9089b8d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_EntityCentralIndexKey_b23fd334-98ad-4c6c-bc3d-4072f9089b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_91f3be87-2393-498c-9bfe-08ac63d3276f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_AmendmentFlag_91f3be87-2393-498c-9bfe-08ac63d3276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e1c47e6c-9ef6-435f-a210-21e7ef7ac221" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_32dfe072-7bd4-4ad5-9097-2029d0197fdf" xlink:to="loc_dei_CurrentFiscalYearEndDate_e1c47e6c-9ef6-435f-a210-21e7ef7ac221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140116279298768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 23,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cidara Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ +X&86 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  O@9A8>YA6/>\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  O@9A8F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "^!
MF%C=F[,X@P0  ,D1   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  O@9A8GZ ;\+$"  #B#   #0
M        @ ''#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "^!F%B7BKL<
MP    !,"   +              "  :,/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( "^!F%@9117U-P$  "<"   /              "  8P0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  O@9A8)!Z;HJT   #X 0  &@
M    @ 'P$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  O@9A899!YDAD!  #/ P  $P              @ '5$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   ?%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cdtx-20240423.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cdtx-20240423.htm">cdtx-20240423.htm</File>
    <File>cdtx-20240423.xsd</File>
    <File>cdtx-20240423_lab.xml</File>
    <File>cdtx-20240423_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cdtx-20240423.htm": {
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20240423",
   "dts": {
    "inline": {
     "local": [
      "cdtx-20240423.htm"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20240423.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20240423_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20240423_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://cidara.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20240423.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20240423.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cidara.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001610618-24-000051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-24-000051-xbrl.zip
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M'O1[W.N.AON=@[V&=[@G#O9@HIZWWSWHC=SNT'7VVOO[ W?0:7O\8$CKCC.
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MA@&E%*DR0^L<:*@?FH^IXZW+$Y-/:'*DK;"8(;;Y$U*?73IQBDL#6<Q?PE#
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M,9(FE>&B#S8W/Q4=%^<!RF2.A06^2A^,55W^VC0K/R$\&[S'L('<H3PJ(&D
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M6_(6\@:1DIIV]?&\75BOTK;"H8;;'0L/EVSSOK>(7K#9[L7H%U!+ P04
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M1E3KNT^Q23!-% ,LBU,0I] 22PD$4@I!8D1D(IWORAT2.?99U4HV6NE&C7#
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M](_,]F* 3Y^!UVNY8QC>54W1W'Z$5=$J436_V#4LJ?$B<FV)50HGQ, CL28
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M.8JDHV'Q=O%$QU,\</CF_D3[TOY_YO#-?P%02P,$%     @ +X&86*&ER*"
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M-;S)A*=PG)OK=PA]?+V%T,>QN I[:H-&I+,SGY-(W[,Q-U\!<QA="G6]%).
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M<U5CR P#E!)+W/MA/Q@JQ^^"DYKD:MP3N\6%@Q+F1W/)(<&E]*7' *8)0SH
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M#O[H(0$0SU]N3*J/-MEXMP/9.UZ)?_@XT/#X7Z[A<8_/:P1X"">PS',4&_I
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MK?"WX"Q\5A936(,QG'^M\8^=Y5_3J@_RM5HW!_? >N[ "HIA1^J&D&"_.##
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MO0^W_?['_M7=T+M^[ZE?>3<P[O[P.2ON<I*^[)ZMOU]/3^%36R.[/&G+CFQ
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MZ6$ ;>(FEAB54'B$J&)4DRG*.VS+^AK6$C17A]*0<2I&$L)$-^E$ 1,%;24
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M5+($Z^Q=RI@&8(OE2'<<0MZVO36;-SC.6QIG&Q WJYN%69;EA.050T%JX6=
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M;.(28VXJ3(].=:=TN<><*]>4N=B@(/QWJ$[4I-/BH/C'*(EFBYE9XCMU;>=
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M(+DK#\%"0PN$84/;K(3ZYY%4;>F;:]7MV:'*]\>P;I_Q$@6_&D-AJ[IB;Y3
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MRJ=2C- J_@KT&2+P7[EQ346&K)=:AU:=<POR2-+<M"@8$R<X':)RC?] ?0Z
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M(1S,J\2+7'T[7NJ4 = _->\*V8&\%>_#B>!=E5D8IV-)4YH]E'\Y^\%S@/]
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M5*D/DT*P/C"4EY'XW\(YFN3T7*&V*,>*P^Y]5RF1IZ<NL++ < $_VC%?L+D
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M6;.7-0#K$M"4B1\59&(HQ@U^585.B'H8&;Q)GJK$"K*)PK8]HH.,(UHP,K!
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MNZ#[>% A3S-QXGXXQ3>L([XXD0E12P^=-DWYFJ/5B!9SN=H5/%D>=R8'<O+
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ML/RK63?5'=>G_]J/-IX>3:_GT'E_M#D^>6E^G>]+^C7"_P=02P,$%     @
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M2Z5Y%<'U.9-; AUZ4HO,SBO]4E%5JTH[1#-A*:$5\3" ^\<3;-U!4AX&C-]
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MJ4DEJKO'A9H(9#).VZ;<P_:&GOT0.J=XV'*JDKJ-I][35%FY?B*KN@9;4DM
MOW&(\RWY7FZ*<,& BV4CIB(;+1DFK82'QEWG7*K\Y\+LIH4LXOD9.J=G7C_P
M8FS6/F?&-QI)#3)- ,Z,<F**>*@Q>\P@9N^"4?U^LVDL#G="S=#@BW'>B&[5
M6A;V2&<W@NF?=PK;>N X9/E>WQ:U973/'JG)!W2' 94:-$0QI=>5!86Y@["
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MYY[OMXHLSD#M$%30=#] FL<2'2"+%_0$5$.@%\RO[4E0YB)765-[AWHW$M,
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M1;T*EG^5>N7OQ]GD#OZZ+F?)C_\#4$L! A0#%     @ +X&86.Z0?-?^*0
MA ,! !$              ( !     &-D='@M,C R-# T,C,N:'1M4$L! A0#
M%     @ +X&86/;'A+EO @  :P<  !$              ( !+2H  &-D='@M
M,C R-# T,C,N>'-D4$L! A0#%     @ +X&86&K:+5_("@  FUP  !4
M         ( !RRP  &-D='@M,C R-# T,C-?;&%B+GAM;%!+ 0(4 Q0    (
M "^!F%CREUJ?#P<   \U   5              "  <8W  !C9'1X+3(P,C0P
M-#(S7W!R92YX;6Q02P$"% ,4    "  O@9A8H:7(H(#F  "WZ@8 &
M        @ $(/P  97AH:6)I=#$P,3(P,C0M,#1X,C0N:'1M4$L! A0#%
M  @ +X&86-VPO70R$@  37@  !@              ( !OB4! &5X:&EB:70Q
M,#(R,#(T+3 T>#(T+FAT;5!+ 0(4 Q0    ( "^!F%BA=(79,C\  ,CJ 0 7
M              "  28X 0!E>&AI8FET,S$R,#(T+3 T>#(T+FAT;5!+!08
1    !P ' -4!  "-=P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>cdtx-20240423_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdtx-20240423.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001610618</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-24">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-04-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Cidara Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36912</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">752-6170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
